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ABSTRACT
THE INVOLVEMENT OF β-CATENIN IN THE INFLAMMATORY RESPONSE
LEADING TO AUTOIMMUNE DIABETES DEVELOPMENT
Arin Zirnheld
July 25, 2013
We identified and characterized a novel defect in β-catenin expression in bone
marrow derived dendritic cells (BMDC) from NOD mice, a model for human Type I
diabetes. This protein is expressed at high levels throughout the lifespan of the mouse
and correlates with increased pro-inflammatory cytokine production by the BMDC and
IFNγ induction by T cells cocultured with the BMDC. These defects, including a similar
pattern of pro-inflammatory cytokine production, are also observed in human monocytederived DC from diabetic patients. After exploring several potential mechanisms
involved in the accumulation of β-catenin in NOD BMDC, we found that β-catenin is
phosphorylated at higher levels in NOD BMDC at two residues associated with increased
stabilization of this protein. Upon inhibition of the two kinases responsible for these
phosphorylations, Akt and PKA, β-catenin expression is reduced. Therefore, β-catenin
accumulates in NOD BMDC through an Akt and PKA-mediated mechanism. We also
explored mechanisms by which β-catenin influences pro-inflammatory cytokine
production and found that inhibition of β-catenin leads to decreased activation of the
transcription factor NFκB, suggesting that pro-inflammatory cytokine production is
increased in NOD BMDC through an NFκB-dependent mechanism. Finally, we
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performed several in vivo experiments aimed at inhibiting β-catenin activity or reducing
β-catenin expression to reduce disease incidence and/or increase survival. Treatment of
NOD mice with quercetin, a β-catenin inhibitor, led to reduced disease incidence and a
decreased inflammatory environment. Transfer of β-catenin siRNA-treated BMDC into
NOD mice also reduced disease incidence. These studies reveal that β-catenin plays a
role in the inflammation leading to diabetes development.
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INTRODUCTION

General Description of Type I diabetes
There are two main types of diabetes: Type I and Type II. Although the symptoms
are similar in these two diseases, they have very different etiologies. While Type II
diabetes results from a lack of insulin production or a reduction in sensitivity to insulin,
Type I diabetes results from an autoimmune process in which the insulin-producing beta
cells of the pancreas are destroyed by a T-cell driven inflammatory process. The World
Health Organization estimates that about 10 percent of the 350 million people in the
world with diabetes have Type I diabetes; most have Type II, which is associated with
obesity and lack of exercise.
Type I diabetes is an autoimmune disease as demonstrated by insulitis, which is
the presence of infiltrating cells in the Islets of Langerhans, antibodies against islet cells,
and T cells that recognize beta cell antigens. Moreover, the disease frequently occurs
with other autoimmune diseases, including celiac disease, Addison’s disease, and
autoimmune thyroid disease [1].
The symptoms of Type I diabetes include thirst, frequent urination, and increased
hunger in childhood or young adulthood [2]. There are several complications caused by
the disease including kidney damage, eye damage and blindness, heart disease and stroke
[2].
Cardiovascular disease is of particular concern for Type I diabetes (TID) patients,
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as they are highly susceptible to coronary heart disease. IL-12, the hallmark pathogenic
cytokine in Type I diabetes development, may play a central role in these high
cardiovascular disease rates. It has been reported that cells in atherosclerotic arteries
produce higher levels of IL-12 than in healthy arteries. Furthermore, IL-12-induced IFNγ
production is also known to exacerbate atherosclerosis, while blockade of IL-12
decreases atherosclerosis in mice [3]. Additionally, Type I diabetes patients have a
variety of elevated inflammatory biomarkers including CRP, nitrotyrosine, monocyte
superoxide, a variety of inflammatory cytokines, VCAM, and pERK [4].

Disease Induction and Progression
It is unknown what initial signal triggers diabetes development, but suggested
triggers include pathogens, commensals and aberrant beta cell death [5]. Regardless of
the nature of the initiating trigger, development of disease is preceded by cellular
infiltration of the pancreatic islets by T cells and macrophages. This infiltration can then
progress to destruction of the beta cells. Although the mechanisms for this destruction
have not been entirely delineated, possibilities include CD8+ T cell cytotoxicity,
macrophage-produced ROS, cytokine-induced apoptosis, and FAS-FAS ligand signaling.
B cells, NK cells, and NKT cells may also play a role in disease development and
progression [6].
Despite the variety of cells involved in infiltration, it is known that CD4+ and
CD8+ T cells and B cells are necessary for disease. B cell-deficient NOD mice do not
develop disease or insulitis [7]. Disease is also delayed or reversed in NOD mice that
underwent antibody-mediated B cell deletion [8]. However, serum from diabetic mice
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does not transfer disease suggesting that B cells may influence disease development
through their role as antigen-presenting cells rather than as autoantibody-producing cells
[5].
CD8+ T cells also play a pivotal role in disease development. The presence of
autoreactive CD8+ cells correlates with beta cell destruction, recurrent autoimmunity
after islet transplant, and graft failure in humans [9]. CD8+ cells can kill beta cells upon
interaction with the Class I molecules expressed on the beta cells [2]. Interestingly, NOD
mice that have been modified to not produce Class I on beta cells do develop insulitis but
not hyperglycemia nor subsequent disease [10].
CD4+ T cells play a key role as well. Transfer of CD4+ T cells into NOD SCID
mice can initiate diabetes, although development of diabetes took twice as long following
transfer of CD4+ T cells from pre-diabetic mice compared to CD4+ T cells from diabetic
mice [11]. Another study found that CD4+ T cells are only able to initiate disease when
CD8+ T cells were present [12]. CD4+ T cells also provide help to B cells and CD8+ cells
and secrete cytokines that create the pathogenic proinflammatory environment that
contributes to disease [2]. Overall, it appears that CD4+ and CD8+ T cells work together
to initiate disease.
Our understanding of disease progression is changing. In the classic model
proposed by George Eisenbarth, a person with a genetic susceptibility encounters an
environmental trigger that leads to progressive beta cell destruction. Only after the
majority of the beta cells (90-95%) are destroyed do the symptoms of diabetes appear.
However, a more modern model has been proposed (See Figure below) [2]. In this more
complex model, a variety of genetic susceptibility genes and environmental triggers
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interact with each other. Loss of immune regulation is also included in this model.
Additionally, the disease is no longer seen as a directly linear process in every patient.
Instead, many patients will experience a relapsing-remitting disease in which beta cell
mass and function fluctuates. Indeed, as many as 60% of patients experience a
honeymoon period in which temporary remission occurs after diagnosis [2].
In the NOD mouse model of disease, disease progression mirrors what occurs in
human diabetic patients. In these mice, disease progression follows a predictable
sequence of events: at 3-4 weeks of age, NOD mice exhibit peri-insulitis in which
mononuclear infiltrates surround the islets but are not yet invasive; by 10 weeks of age,
CD4+ and CD8+ cells along with NK cells, B cells, DC, and macrophages have infiltrated
the islets resulting in insulitis [5, 13].
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Prevention, Prediction, and Treatment of Type I diabetes
Type I diabetes is a devastating chronic disease that requires continuous care, and
has enormous financial and social impacts, e.g., increased divorce rates in families with
children with the disease. Current treatments for Type I diabetes are limited to insulin
injections or pumps [2]. Despite the impact of technological progress on diagnostics and
treatments, the modern life style has made it more difficult for diabetic patients to control
blood glucose levels. However, T1D can be predicted with some accuracy which leads to
the possibility of preventative treatments. One study found that in individuals with risk
factors for T1D, including having a relative with T1D and having autoantibodies against
islet cells (ICA), glucose tolerance tests can predict the onset of disease with a 0.66
accuracy [14]. Another study found that 89% of children with two or more different islet
autoantibodies progressed to T1D [15]. Additionally, children with persistently high
levels of insulin autoantibody (IAA) had a 100% chance of progression to T1D. Other
autoantibodies, such as those against GAD65 or IA2 (islet antigen 2)/ICA512 (islet cell
autoantigen 512), did not show the same correlation with disease progression [15].
Finally, genetically high-risk children, those with the DR3/4-DQ8 HLA genotype, who
were found to have multiple autoantibodies at an early age were much more likely to
develop diabetes than those with non-high risk HLA genotypes, only one autoantibody, or
presence of autoantibodies at a later age [16].
Promisingly, various therapies have successfully prevented or cured diabetes in
NOD mice. Some of the various successful therapies in mice include anti-CD3 antibody
treatment, which has resulted in remission in a variety of studies [17-19]. However,
several studies also showed no effect of this treatment when therapy started at different
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time points [19-22]. Additionally, TNF-α administration has resulted in disease
protection in various studies, although at least one study found an exacerbating effect
[23]. These conflicting findings are likely due to differences in timing and length of
administration [23]. It does not appear that the success of preventative treatments
depends on early administration as evidenced by the success of several treatments that
began at more than 4 weeks of age, including some anti-CD3 antibody studies, CTLA-4
antibody treatment, and TNFα administration [23]. Additionally oral feeding of insulin
and GAD65 reduced diabetes incidence in NOD mice by inhibiting islet infiltration and
IFNγ production [24].
Several therapies first demonstrated to be effective in NOD mice have been tried
in human clinical trials. These include anti-CD3 in recently diagnosed diabetic patients
which resulted in reduced requirements for insulin and oral insulin [25-27]. Although the
treatment was administered for a short time, its protective effects lasted for at least 4
years. Younger patients, between the ages of 17 and 27 years old and those patients in the
early stages of beta cell destruction responded better to the therapy than older patients
and those in later stages of disease [28]. Studies treating high risk pre-diabetic individuals
with oral insulin, plasmid-encoded proinsulin, or subcutaneous GAD65 have also been
performed. Oral insulin treatment in individuals with anti-insulin autoantibodies reduced
incidence, but this effect disappeared once treatment ended [29]. Pro-insulin plasmid
treatment resulted in preservation of high C-peptide levels and reduced CD8+ T cell
infiltration [30]. Subcutaneous GAD65 had no effect on diabetes incidence or levels of Cpeptide [31].
Interestingly, several studies have shown that Vitamin D (1α,25-dihydroxyvitamin
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D) can modulate the immune responses in NOD mice. High doses of Vitamin D
administration to NOD mice reduced the incidence of diabetes to 8% [32]. 1,25Dihydroxyvitamin D3 has been shown to inhibit IL-12 production by activated dendritic
cells and macrophages by downregulating NFκB activation [33]. Vitamin D has been
used in human clinical trials as well. However, in one study, a dose of 0.25 ug of Vitamin
D had no effect on beta-cell function in recently diagnosed T1D patients [34]. In another
study, pregnant women whose children were at risk for T1D were given Vitamin D
supplements. Supplementation was not associated with decreased risk for T1D for their
children later in life [35].
Additionally, there have been a variety of studies using cell-based therapies such
as T regulatory cells (Tregs). Treg transfer into NOD mice can reverse diabetes after
onset [36, 37]. Similarly, in humans, administration of Tregs to recent-onset diabetic
children led to increased C-peptide levels [38]. Various treatments aimed at restoring beta
cell function have been tried, all with varying degrees of success. It is likely that
combination therapies will be necessary to fully prevent or cure T1D [2]. Despite several
promising therapies, Type I diabetes treatment continues to consist of insulin therapy.
Therefore, the search for effective therapies must continue.

The Non-Obese Diabetic (NOD) Mouse
The NOD strain was established by selectively breeding a female mouse that had
spontaneously developed polyuria, glycosuria, and weight loss. Female NOD mice
typically have a diabetes incidence of 70-80% and onset of disease at 10 weeks, while
males have an incidence of about 20% and onset at 20 weeks, although there is variability
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among colonies [39]. Some of this variability may be due to differences in gut
microbiota composition. For example, the presence of segmented filamentous bacteria
(SFB) has been found to correlate with protection from diabetes in NOD females as
compared to female mice lacking SFB from the same facility [40]. The symptoms of
disease in NOD mice include polyuria, glycosuria, hyperglycemia, insulin deficiency,
ketonuria, and rapid weight loss. Mice typically die within 1-2 months of onset of
disease [39].
Disease pathogenesis in NOD mice is similar to humans; they exhibit the presence
of similar pancreatic autoantigens including glutamic acid decarboxylase (GAD), insulin,
and ZnT8 (a zinc transporter) [41]. Autoreactive CD4+ and CD8+ T cells infiltrate the
pancreas in both the mouse model and human patients. NOD mice are susceptible to
other autoimmune diseases, similar to some T1D patients [13]. Additionally, NOD mice
have a nonaspartic acid substitution at position 57 of the beta chain of their unique MHC
molecule. A similar substitution is seen in human susceptibility loci in the DQ beta chain
[13].

Autoimmunity, Tolerance, and Tregs in Type I diabetes
In healthy immune system development, most T cells that recognize beta cell selfantigens are deleted [42]. However, self-reactive T cells against beta cells are found in
T1D patients as well as healthy individuals. Therefore, other mechanisms control the
self-reactivity of these T cells: ignorance, anergy, deletion, and regulation [43].
Suppressor cells, characterized as CD4+ T cells and later described as regulatory T cells,
have been found to be capable of protecting NOD mice, a powerful mouse model for
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T1D, from diabetes [41]. Foxp3 Tregs are the main focus of regulatory cell research, but
other cells, such as NKT cells, can regulate autoimmunity in T1D. For example, various
studies found that activation of NKT cells with alpha-galactosylceramide led to a shift
towards a Th-2 phenotype in treated mice and led to protection of islets transplanted into
diabetic mice [44, 45].
Various pieces of evidence indicate defects in Tregs are important in development
of disease in NOD mice. For example, B7-1 knockout mice and CD28 knockout mice
have greatly reduced percentages of CD4+CD25+ Tregs and develop T1D very quickly
[46]. However, disease progression can be slowed in NOD/SCID mice that have been
induced to have diabetes with administration of CD28 deficient splenocytes by
adoptively transferring CD25+ Tregs [46]. Additionally, progression of diabetes has been
associated with both decreased percentages of Tregs in the pancreatic lymph nodes of
NOD mice versus control mice [47] as well as decreased suppressive activity of Tregs
[48, 49]. On the other hand, another study showed no difference in frequencies of Tregs
[50]. However, Treg function and ability to proliferate may decline with age [49].
Additionally, decreased suppressive activity of Tregs and decreased sensitivity to
regulation of pathogenic T cells may contribute to disease [48, 51].
Despite these studies that clearly indicate a protective role for Tregs in T1D in
NOD mice, studies on Tregs in humans have given contradictory and difficult to interpret
results [43]. For example, one study found reduced numbers of Tregs in PBMCs of
diabetic patients [52], while others have found no differences [53-55]. Additionally, one
study found no difference in the suppressive capacity of Tregs from diabetic patients [54],
but several studies did find qualitative differences in T cell populations from diabetic
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patients including reduced suppressive capacity [53, 55] and increased pro-inflammatory
cytokine production [55].

Genetic Factors in T1D
A variety of genetic and environmental factors have been proposed as
contributing to the development of Type I diabetes [6]. There are a few single locus
genetic conditions that can result in T1D in humans. These include IPEX and
autoimmune polyendocrine syndrome Type I. In IPEX, multiorgan autoimmunity,
including that of the pancreas, occurs as a result of a mutation in the gene for Foxp3 and
subsequent dysfunction of regulatory T cells [56]. This disease is modeled in the scurfy
mouse [57]. Autoimmune polyendocrine syndrome results in autoimmune diabetes 20%
of the time as a consequence of a mutation in AIRE, a protein important for expression of
self-antigens in the thymus leading to self-tolerance [58].
More often, however, T1D is the result of a complex interplay between multiple
genetic loci. In humans, the MHCII molecules HLA-DQ2 and HLA-DQ8 are the greatest
risk factors for disease development [6] with the MHC locus contributing 40% of the
susceptibility to T1D [41]. There is increased risk for DR3/4 as well, although the risk
has been reported to be small [59]. Class I haplotypes, including HLA-A genotype
A1and A2 have also been associated with T1D development. These genes, when
combined with high-risk Class II haplotypes, correlate with high incidence and earlier
appearance of islet autoantibodies [60]. These MHC susceptibility genes were identified
very early on and are found within the chromosomal region referred to as IDDM 1
(Insulin-Dependent Diabetes Mellitus) [2]. There are also several identified HLA
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haplotypes that confer disease protection in humans: DRB1*1501-DQA1*0102DQB1*0602, DRB1*1401-DQA1*0101-DQB1*0503, and DRB1*0701-DQA1*0201DQB1*0303 [61]. The MHC genes play a large role in disease susceptibility in NOD
mice as well: the cells of these mice have a unique MHC II molecule called H2g7 [13].
However, NOD mice with the MHC molecule from diabetic-resistant B6 mice and B6
mice with this MHC molecule inserted do not develop diabetes, indicating that H2 g7 is
not sufficient for disease development.
Many other non-HLA genes have been associated with T1D development in
humans indicating that the disease has a complex genetic component [62]. Other
associated genes include the 5' flanking region of the insulin gene, the PTPN22 gene, the
CTLA4 gene [41], the IL2RA gene, and the IFIH1 gene [2]. The insulin gene is found
within the chromosomal region referred to as IDDM2 found on chromosome 11 [2]. It
was reported that a polymorphic region of the insulin gene was associated with T1D in
Caucasians [63]. The PTPN22 gene encodes the protein lymphoid protein tyrosine
phosphatase, which dephosphorylates Lck and Zap70, Vav, CD3ε, and valosin containing
protein, which is an important process in the negative regulation of TCR signaling [64].
Mutations in this gene may lead to aberrant T cell signaling and subsequent
autoimmunity. CTLA4, an important negative regulator of lymphocyte proliferation [65],
is found within the IDDM 12 region and can play a role in T1D and other autoimmune
diseases as well [66, 67]. It has been shown that knocking out CTLA-4 in mice leads to
infiltration of lymphocytes in various organs, including the pancreas [65]. There are also
variations in the alpha chain of the IL-2 receptor, which is involved in Treg
differentiation, associated with T1D development [8, 68, 69]. Additionally, the gene for
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IL-2 is located on chromosome 4 in an area identified as containing susceptibility genes
[70]. Finally, several studies have indicated a link between T1D and the IFIH1 gene,
which encodes a cytoplasmic sensor protein that recognizes picorna viruses such as
coxsackie virus, which may play a role as a triggering factor in diabetes development [2].
Higher levels of IFIH1 are found in the PBMCs of individuals with the susceptible
polymorphisms of this gene [71]. Additionally, several polymorphisms of this gene have
been found to be protective for T1D [72].
The NOD mouse model has provided several insights into the genetic basis of
T1D. In this model, several chromosome segments have been associated with disease
development. These genetic loci, called Idd, include various genes associated with Type I
diabetes. Interestingly, Idd5 in NOD mice has been shown to contain the gene for
CTLA4 [73]. Although the IL-2 receptor has not been associated with disease, the IL-2
gene itself is found within the chromosomal region Idd3 in NOD mice [74]. Despite the
fact that mutations in PTPN22 have been shown to be an important genetic risk factor for
autoimmunity in humans, knock down of PTPN22 expression in NOD mice led to
protection from disease [75].

Environmental Factors in T1D
Although T1D certainly has a genetic component, environmental factors also play
an important role in disease development and incidence. This is evidenced by twin
studies in which monozygotic twin concordance rates are low at around 50% indicating a
strong environmental component [76]. Additionally, Type I diabetes incidence has been
increasing in recent years. For example, in Finland incidence has increased from
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20/106/year in 1972 to 65/106/year currently [41]. In Auckland, New Zealand, incidence
increased from 7.6 per year in 1990-1991 to 8.9 a year in 2008-2009 [77]. These large
increases in incidence cannot be explained by genetic factors alone, and therefore there
must be some environmental trigger. Based on epidemiology data and data generated in
the NOD mouse model of Type I diabetes, the proposed environmental factors include
viruses [78, 79], bacterial pathogens, and increased hygiene standards.
Epidemiological data points to a role for viral infection. In a meta-analysis of 33
studies, it was found that enterovirus infection correlates strongly with T1D development.
There was almost 10 times greater occurrence of enterovirus infection in children with
T1D as compared to control children [80]. Maternal infection with coxsackie virus
during pregnancy was also found to correlate with T1D development in the children [8183]. Beta cells can be directly infected by coxsackie virus, and infection by this virus
correlated with loss of beta cell function [84][[85]. Interestingly, a molecule found in the
cocksackie virus is very similar to GAD, one of the identified autoantigens in T1D,
suggesting that molecular mimicry may play a role in T1D [86]. However, another study
reported that infection of NOD mice with coxsackie virus before disease onset may
actually be protective suggesting that timing is key in the protective versus causative
effect of the virus [87].
One study reported an increase in HLA Class I molecule and IFNα expression in
the islets of T1D children, suggesting a role for viruses in the disease [88]. Other viruses
have been implicated in T1D as well: cytomegalovirus [89], parvovirus [90],
encephalomyocarditis virus [91], and rotavirus [92]. However, in patients, it is difficult to
determine if viruses are a causative disease agent or if increased susceptibility to viral
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infections is a consequence of the disease. Additionally, in humans it has been shown
that various factors relating to cleanliness and decreased antigenic stimulation are
associated with TID. The hygiene hypothesis postulates that increases in various
hygienic factors, including the absence of an older sibling [47], lack of exposure to viral
infections [93] and lack of helminth infections [94], lead to increased susceptibility to
Type I diabetes as well as other autoimmune diseases. Although this contradicts the data
showing a link between particular viruses and Type I diabetes, it is possible that certain
infections trigger disease, while others are protective. Additionally, it has been shown
that there are differences in the intestinal microbiota between autoantibody-positive
children and autoantibody-negative children. Autoantibody-positive children had
particularly low levels of lactate and butyrate-producing bacteria, suggesting that the
composition of the entire microbiota, not one particular organism, may influence disease
[95]. A second study showed that the ratios of various groups of bacteria in diabetic
children were significantly different than in healthy children [96]. Other non-pathogenic
factors have been associated with the development of T1D in humans. These include
ingestion of cow’s milk [97, 98] and gliadin and Glb1, both proteins found in wheat [99,
100].
Various data generated with animal models of T1D also support an environmental
effect in Type I diabetes. NOD mice raised in pathogen-free environments have higher
rates of diabetes development than NOD mice raised in less clean environments [41].
Additionally, various pathogens can protect NOD mice from disease, including viruses
such as Coxsackie B and lymphocytic choriomeningitis virus [93, 101], and parasites
such as Schistosoma mansoni or only the eggs [102], and Trichinella spiralis or
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Heligmosomoides polygyrus [103]. Finally, bacteria in the gut play an important role in
the development of diabetes. NOD mice raised under specific-pathogen free conditions
and lacking Myd88 have altered microbiota composition and do not develop diabetes.
However, germ-free mice lacking MyD88 do develop diabetes, although this can be
attenuated by transferring the microbiota of specific germ-free NOD MyD88 knockouts
indicating a role for te microbiota in disease development [104].

Defects in APC in T1D
A variety of defects in antigen presenting cells (APC) have been associated with
T1D development in both human patients and NOD mice. In one study, dendritic cells
from type I diabetic patients exhibited decreased maturation, reduced ability to cluster,
and reduced ability to stimulate autologous and allogeneic T cell responses [105]. In
another study, the yield of DC cultured from monocytes was lower in relatives of T1D
patients as compared to control cells. A lower proportion of DC from T1D relatives
expressed CD1a, B7-1, and B7-2 when compared to control cells, and the expression of
these molecules was lower in relatives' cells. Overall, cells from relatives of Type I
diabetes patients had defects similar to those found in Type I diabetic patients [106]. In a
study performed on twins discordant for Type I diabetes, B cells from the diabetic twin
displayed increased turnover of MHC Class II at the cell surface, inadequate
glycosylation of MHC II, and reduced display of antigens resulting from decreased
expression of li p35, which brings MHC Class II to the cell surface [107].
Studies using NOD APC have also reported a variety of defects. NOD BMDC
showed low expression of MHC Class I and Class II and low levels of B7.1 and B7.2 and
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CD40 as compared to BMDC from non-diabetic B6 mice. NOD BMDC cultures also
yielded fewer mature cells than B6 cultures. There was also a higher ratio of DC:
responder T cells needed to induce proliferation with NOD BMDC (1:10) than with B6
BMDC (1:100). Additionally, NOD BMDC produced lower levels of IL-12 than B6 cells
upon LPS stimulation [108].
Several other studies have found defects in NOD APC. Proliferation of T cells in
response to antigen (hen egg lysozyme) was lower in NOD cells than in NOR cells
(diabetes-resistant) due to a defect in APC activation in NOD mice. NOR macrophages
produced more intracellular GSH (a reducing agent that breaks disulfide bonds in antigen
molecules) resulting in more antigen processing than in NOD mice [109]. Another study
found that NOD bone marrow cells proliferated and matured at lower levels in the
presence of CSF-1 as compared to cells from non-diabetic mice. MHC-I expression was
also lower in NOD macrophages compared to control cells [110].

Involvement of IL-12 and IFNγ in infection
IL-12 has a very important role in clearing infection resulting from bacteria,
intracellular protozoa, and fungi by helping to generate a proinflammatory Th1 response.
IL-12 induces this proinflammatory environment by stimulating T cells and NK cells to
produce GM-CSF, TNF, and IFNγ. In a healthy immune system, IFNγ activates
phagocytes, such as macrophages, to destroy pathogens. Cells that produce IL-12 include
DCs, macrophages, monocytes, and neutrophils. IFNγ can also be produced by NKT
cells, CD8+ T cells, gamma delta T cells, macrophages, DC, and B cells [111].
IL-12 is a heterodimer composed of two chains: p35 and p40 [112]. IL-12 is
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produced in response to recognition of pathogens through TLRs. Stimulation of TLR7
with R848 and TLR9 with CpG DNA results in robust production of IL-12 from BMDC.
Stimulation of TLR4 with LPS and TLR 3 with Poly(I:C) results in IL-12 production, but
at lower levels than in response to TLR7 or TLR9 stimulation [113]. TLR11 and TLR12
have also been found to be involved in IL-12 production in response to T. gondii
infection. TLR12 was found to be important in the recognition of this pathogen by
plasmacytoid DC, whereas both TLR11 and 12 were necessary for recognition by DC and
macrophages. Signaling through TLR12 in pDC induced IL-12 and IFN production
which in turn induced IFN production by NK cells [114]. Additionally, it has been
shown that use of IFN and CD40 stimulation can increase TLR-stimulated IL-12
production [115].
Once IL-12 is produced, it binds the IL-12 receptor, found mainly on activated T
cells and NK cells, but on other cell types as well. This receptor has two chains: IL12Rβ1 and IL-12Rβ2. Signaling through the receptor activates the Jak-STAT signaling
pathway, which results in STAT4-induced production of IFN [111].

Inflammatory cytokines and induction of pathogenic cells in T1D
Several lines of evidence implicate inflammatory cytokines, especially IL-12 and
IFNγ as mediators of T1D development. Genetic studies have found an association
between the IL-12 gene and T1D. One study found that certain alleles for the IL-12B
gene, which encodes the p40 subunit of IL-12, have been associated with T1D risk.
While various IL-12B polymorphisms don't necessarily correlate with susceptibility in all
people, an allele encoding higher IL-12 production does correlate with increased risk for
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disease in a subset of T1D patients [116]. Another study identified IDDM18, a genetic
locus near the IL-12p40 gene as contributing to T1D resulting from a polymorphism in
the 3' untranslated region of the gene. Individuals with the susceptible allele have
increased IL-12 production [117].
Studies in NOD mice also provide support for an important role for IL-12 and
IFNγ in disease development. IL-12 administration to NOD mice accelerates disease and
is associated with infiltration of T cells into the pancreatic islets and loss of islets. More
importantly, these T cells produce high levels of IFNγ upon stimulation [118]. In
addition, NOD mice deficient in IL-12p40 have reduced incidence of disease as
compared to control NOD mice and show almost complete lack of cellular infiltration in
the pancreas. Even after LPS stimulation, NOD mice deficient in IL-12 have 5% the
IFNγ serum levels of their IL-12 replete counterparts [112].
A variety of APC, including macrophages from NOD mice have been found to
produce aberrant levels of IL-12. Upon stimulation, macrophages from prediabetic NOD
mice produce high levels of IL-12 when compared to diabetes resistant strains of mice
[119]. One study found this may result from defective tyrosine phosphorylation of the cRel protein, a member of the NFB family. Rel proteins bind to sites in the IL-12p40
promoter, influencing IL-12 production [120, 121]. IL-12 mRNA was also elevated in
NOD mouse macrophages [120]. In another study, a site within the p40 promoter was
found to bind Rel proteins upon stimulation with several molecules derived from IL-12inducing pathogens including LPS and LTA in macrophages [122]. Bone marrow derived
and splenic-derived DC from NOD mice were also found to be more sensitive to
particular stimuli such as IL-12, anti-CD40 Ab, TNFα, and LPS and secrete more IL-12
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than DC from diabetes-resistant mice. [121]. In another study, transfecting BMDC from
NOD mice with siRNA against NFB resulted in reduced NFB binding to the DNA and
the suppression of IL-12 production upon LPS stimulation. Administering cells treated
with this siRNA to NOD mice at 6-7 weeks of age resulted in protection from diabetes.
At 30 weeks of age, treated mice had markedly reduced islet infiltration as compared to
control-treated mice [50]. Injecting NOD mice with IL-12 also accelerates disease [118].
Contradictorily, intermittent intraperitoneal dosing of IL-12 can reduce diabetes in NOD
mice [123]. These results likely stem from differences in dosage and timing.

β-catenin and the Wnt signaling pathway
The first Wnt protein, a group of secreted signaling glycoproteins, was identified
in Drosophila and named Wingless [124]. Wingless signaling induces nuclear
translocation of an intracellular protein named Armadillo or β-catenin in vertebrates
[124]. The Wnt pathway is involved in development, tissue specification, and cellular
migration [125]. Mutations in this pathway are associated with cancer, especially colon
and breast cancer, due to this pathway’s role in cell survival and growth [125-127]. Wnt
proteins bind to frizzled receptors. Various proteins bind to Wnt proteins and block their
interactions with their receptors [128]. There are canonical Wnt pathways that result in
activation of β-catenin signaling and non-canonical Wnt pathways that do not activate catenin signaling. There are a variety of Wnt proteins, receptors, and coreceptors which
allow for a large diversity of responses [125].
-catenin, an important intracellular protein involved in the Wnt signaling
pathway, has 12 ARM domains, each of which is comprised of a specific 42 amino acid
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motif. These ARM repeats form a long positively charged groove that allows -catenin
to bind to other proteins and complexes including the cadherin complex at the cell
membrane, the degradation complex in the cytoplasm, and transcription factors in the
nucleus [8]. In resting cells, -catenin complexes with E-cadherin at the cell membrane
and plays a role in maintaining cell junctions. Excess -catenin not bound to E-cadherin
forms complexes with several other proteins in the cytoplasm to form a multiprotein
destruction complex. These other proteins include axin, APC, and GSK3. In the
absence of Wnt signaling, -catenin is phosphorylated by casein kinase I at Ser45 and
subsequently phosphorylated by GSK3 on the serine/threonine residues 41, 33, and 37
[129]. TCRp then ubiquitinates -catenin, targeting it for proteasomal degradation
[130]. In contrast, upon Wnt signaling, Dishevelled recruits GBP/Frat-1 which displaces
GSK3 and allows -catenin to escape degradation [131]. Upon stabilization, -catenin
accumulates in the cytoplasm and can then translocate to the nucleus where it binds to
TCF/LEF transcription factors and influence transcriptional activity in the cell [132].
-catenin and Wnt signaling have been associated with metabolic regulation and
Type II diabetes development. Components of the Wnt pathway have been found to be
involved in beta cell proliferation, cholesterol metabolism, insulin secretion, and
production of GLP-1 (glucagon-like peptide-1). Additionally, TCF4, a transcription
factor that binds to β-catenin, has been identified as a susceptibility gene for Type II
diabetes [133]. Interestingly, the human LRP5 gene, which codes for one of the Frizzled
coreceptors LRP5, is associated, although not strongly, with Type I diabetes. This gene is
found within IDDM 4, a chromosome region associated with Type I diabetes and is
involved in insulin-secretion [107].
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Modulation of β-catenin at the cell membrane
β-catenin plays an important role in cell adhesions due to its ability to complex
with E-cadherin at the cell membrane. Binding of-catenin to E-cadherin protects Ecadherin from degradation [79]. Additionally, the interaction between these two proteins
helps regulate -catenin signaling in the cell: one study found that overexpressing
cadherins resulted in sequestration of the cytosolic pool of -catenin leading to reduced
-catenin signaling [134]. Another study found that E-cadherin competed with LEF-1,
one of -catenin’s transcriptional factor binding partners, for binding to -catenin. In Ecadherin -/- stem cells, -catenin accumulated and interacted with LEF-1 at higher levels.
However, transfecting these cells with E-cadherin resulted in the restoration of -catenin
to the cell membrane [135]. These studies suggest that E-cadherin recruits -catenin to
the cell membrane and keeps it from accumulating in the nucleus where it can induce
transcription.
This important protein interaction is regulated through the action of several
kinases that can phosphorylate either -catenin or E-cadherin at various residues. These
phosphorylations can result in increased or decreased strength of the interaction between
the two proteins. For example, phosphorylation of E-cadherin on Ser834, 836, and 842
by CK2 and GSK3 enhances the affinity of E-cadherin for binding to -catenin [8].
However, phosphorylation of E-cadherin at Ser846 by CK1 destabilizes the E-cadherin/catenin complex [136]. Phosphorylation of E-cadherin at Tyr831 and 860 by src kinase
also inhibits the interaction between -catenin and E-cadherin [137].
Similarly, phosphorylation of -catenin on Tyr654 by Src kinase can reduce this
interaction [8, 138]. In contrast, phosphorylation of -catenin by PKD1 at residues
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Thr112 and 120 increases β-catenin’s interaction with E-cadherin. One one hand,
mutating these two residues resulted in increased nuclear translocation of -catenin and
alteration of -catenin transcriptional activity. On the other hand, overexpression of
PKD1 resulted in decreased -catenin transcriptional activity and cell proliferation [113].
It has also been shown that the interactions between other catenins and cadherins
can be modulated by phosphorylation. Phosphorylation of -catenin at Tyr142 by the
tyrosine kinases Fen or Fyn leads to disruption of the interaction between -catenin and
-catenin, another protein important in forming cell-cell contacts [139]. This
phosphorylation also increases binding with BCL9-2, a protein associated with nuclear
transport of -catenin [140]. Additionally, Abl kinase can phosphorylate -catenin on
Tyr489, leading to decreased interaction with N-cadherin (a cadherin found in neurons),
and increased nuclear translocation of -catenin [141].

β-catenin modulation in the cytoplasm and nucleus
In addition to the -catenin found at the cell membrane, a second pool of catenin is found in the cytoplasm and can be modulated via degradation or stabilization.
-catenin can form a destruction complex with several other proteins including axin,
APC, CK1, and GSK3. Within this complex, axin acts as a coordinator of
phosphorylation events while APC promotes the movement of -catenin through the axin
complex [8]. CK1 phosphorylates -catenin at Ser45 [120, 129] and primes the-catenin
molecule for phosphorylation by GSK3 on Ser33 and 37 and Thr41 [142]. Once catenin is phosphorylated by GSK3, it is recognized by beta-TrCP, an Fbox protein
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involved in ubiquitination [130]. Ubiquitinated -catenin is degraded by the proteasome
as evidenced by one study which found that treatment of cells with proteasome inhibitors,
including ALLN and lactacystin, resulted in accumulation of higher-molecular weight catenin in the cytoplasm. These higher-molecular weight molecules indicated the
presence of ubiquitinated -catenin. Inhibition of the proteasome resulted in longer
stability of -catenin in these cells. Additionally, a site on -catenin composed of
residues 33-45, is required for ubiquitination. This site is the GSK3 consensus sequence
[143]. It has also been found that PKC can phosphorylate -catenin on Ser33 and 37
leading to its degradation [144].
In contrast, phosphorylation of other residues leads to -catenin’s stabilization.
Activation of the PI3K pathway has been found to increase -catenin stability and
nuclear translocation. Upon signaling by a variety of factors including growth factors
and insulin, PI3K becomes activated to produce 3-phosphoinositides which bind to the
PH domain of Akt, also known as PKB. Akt is then recruited to the cell membrane where
it can be phosphorylated [145] at Thr308 by PDK1 or Ser473 by PDK2 [146-148],
leading to its activation. Akt can then phosphorylate other proteins, including GSK3 on
Serine 21 and GSK3 on Serine 9 [149] or -catenin on Serine 552 [150]. These
phosphorylations result in decreased activity of GSK3 [149] as well as direct stabilization
of -catenin, respectively [150].
One study found that Akt phosphorylates -catenin on Ser552 which causes catenin to dissociate from the E-cadherin complex and allows it to accumulate in the
cytoplasm and nucleus [150]. Additionally, mutation of PTEN (which in its non-mutated
form inhibits PI3K activity) results in activation of Akt and leads to higher levels of 23

catenin phosphorylated at Ser552 and increased nuclear localization and transcriptional
activity in intestinal stem cells [8]. It has also been found that prostaglandin E2 activates
PI3K signaling which results in Akt activation. Prostaglandin E2 treatment induced the
dissociation of GSK3 from the destruction complex, which resulted in decreased
phosporylation of -catenin by GSK3β and subsequent degradation. Upon PGE-2
stimulation, -catenin can therefore accumulate in the cytoplasm, translocate to the
nucleus, and induce transcription through an Akt-dependent mechanism [151]. Another
study found that LPS stimulation of human alveolar macrophages resulted in activation of
PI3K. Upon PI3K activation, Akt was phosphorylated at Ser473 and GSK3 was
phosphorylated at Ser21 and 9. This stimulation resulted in increased nuclear
accumulation of -catenin and transcriptional activity [152].
PKA activity has also been implicated in the regulation of -catenin stability and
signaling. PKA is activated, not upon phosphorylation, but upon cAMP binding which
results in the release of the catalytic subunits of PKA from the regulatory subunits.
Although PKA is not activated by phosphorylation of particular residues, it has been
found that PDK1 can phosphorylate the catalytic subunit at Thr197 resulting in optimal
catalytic activity [153, 154]. PKA has also been shown to phosphorylate GSK3 at Ser
21 and GSK3 at Ser9 which results in inactivation of these enzymes [155]. More
importantly, PKA has been found to phosphorylate -catenin at Ser552 and Ser675.
These phosphorylations resulted in increased transcriptional activity by -catenin [156].
Mutation of the Ser675 site reduced -catenin signaling induced by PKA activation, and
phosphorylation of Ser675 increased the interaction between -catenin and CBP, a
transcriptional coactivator, suggesting that PKA can activate directly -catenin via
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phosphorylation at this residue.
Another study found similar results for the role of Ser675 phosphorylation. In a
mouse model in which the gene for -catenin was modified so that it had a reduced
affinity for E-cadherin, there was increased phosphorylation at Ser675 by PKA.
Increased phosphorylation at Ser675 correlated with increased nuclear translocation and
transcriptional activity of -catenin. These data suggest that phosphorylation at Ser675
leads to subsequent increased nuclear translocation and activity [157]. In addition to
increasing -catenin’s transcriptional activity, it has been shown that PKA activity is also
associated with increased nuclear and cytoplasmic accumulation of -catenin. PKA
phosphorylation of -catenin at Serine 675 was found to inhibit ubiquitination and
degradation of -catenin without interfering with its ability to bind to the degradation
complex [158]. Additionally, when APCMin/+ mice were treated with a PKA antagonist,
Rp-8-Br-cAMPs, intestinal -catenin expression, nuclear translocation, and expression of
target genes were reduced. The same antagonist blocked PGE2 induced phosphorylation
of -catenin at Ser 552 and Ser 675 by PKA in a colon cancer cell line [159]. These
data suggest that PKA plays a key role in stabilization and activity of -catenin. The
modulation of -catenin by PKA, PKB and GSK3 is summarized in the figure below.
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Modulation of -catenin expression [159]
Finally, JNK has been reported to affect -catenin stability. Wnt signaling
activation of Rac1 leads to activation of JNK which phosphorylates -catenin at residues
Ser191 and Ser605. These phosphorylations stabilized -catenin in the cytoplasm and
result in increased nuclear translocation [160].
Overall, these data indicate that the stabilization or degradation of -catenin is
regulated through a complex array of mechanisms, signaling pathways, and stimuli.

β-catenin nuclear translocation and transcriptional activity
The mechanism by which -catenin translocates to the nucleus is not well known.
It has been shown that -catenin has no nuclear location signal (NLS) that would help it
travel from the cytoplasm to the nucleus. However, the protein has been found to bind to
the nuclear envelope directly. Additionally, translocation of -catenin is energy-
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dependent, suggesting that it can be imported into the nucleus independent of a signal
sequence or other proteins [134].
Despite its suspected ability to translocate independently of a signal sequence,
several studies have reported the involvement of other proteins in -catenin localization
from cytoplasm to nucleus or nucleus to cytoplasm. In one study, TCF4 and
BCL9/Pygopus were found to recruit -catenin to the nucleus, while APC and axin were
responsible for enrichment of -catenin in the cytoplasm. However, all of these factors
function to retain -catenin either in the cytoplasm or nucleus instead of acting as active
transporters [161]. Overall, nuclear accumulation of -catenin may be the result of
excess protein simply moving from the cytoplasm to the nucleus instead of a regulated
transport mechanism.
Sumoylation of -catenin is another potential mechanism regulating nuclear
translocation since -catenin contains candidate sumoylation sites. However, no studies
have been performed to examine -catenin sumoylation. There are three mammalian
SUMOs: SUMO-1, SUMO-2, SUMO-3. n the other hand, one study has found that
TCF4, which binds to -catenin and induces transcription along with β-catenin, is
sumoylated. Moreover, treatment with PIASγ, a SUMO E3 enzyme, increased -catenin
transcriptional activity. In contrast, Axam, a desumoylation enzyme, inhibited -catenindependent TCF4 activation [107]. This study shows that sumoylation is an important
post-translational modification in the β-catenin signaling pathway and can affect
transcriptional activity.
Just as -catenin can travel from cytoplasm to nucleus, it can also travel in the
reverse direction. Axin not only acts as a member of the degradation complex, but also
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acts as a nuclear export shuttle for -catenin from the nucleus to the cytoplasm as
evidence by fluorescence microscopy experiments in which Axin and -catenin
translocated and colocalized to the cytoplasm [162]. Ranbp3, a protein found to interact
with -catenin, was also identified as a potential nuclear exporter of -catenin.
Overexpression of Ranbp3 led to increased accumulation of active -catenin in the
cytoplasm versus nucleus and reduced -catenin transcriptional activity. Furthermore,
depletion of RanBP3 resulted in nuclear accumulation of -catenin [163].
Once -catenin has reached the nucleus, it binds with other transcription factors
and coactivators to influence gene transcription. -catenin binds to members of the TCF
and LEF families of transcription factors. Additionally, -catenin binds to the
transcriptional coactivators CBP (creb-binding protein) [164, 165] and p300, two related
acetyltransferases [165]. Phosphorylation of TCF and LEF factors enhances their binding
affinity to -catenin, and therefore affects -catenin transcriptional activity [8]. -catenin
signaling influences the transcription of a huge variety of genes. For example, Ecadherin is transcribed at lower levels upon -catenin signaling [166, 167]. Many other
genes are upregulated in response to -catenin transcriptional activity: CTLA-4, [168], cMyc [153], cyclin D1 [169, 170], Tcf-1 [171], Lef-1 [172, 173], and Axin2 [174-176].
Several inhibitors of -catenin transcriptional activity have been discovered.
These inhibitors target the ability of -catenin to bind to transcription factors and
coactivators. One molecule, ICG-001, inhibits -catenin/TCF transcriptional activity by
disrupting the interaction between -catenin and CBP, but not with p300. It was found
that ICG-001 can inhibit colon tumor growth [177] and reduce the transcription of gene
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targets of -catenin/TCF including cyclin D1 and c-myc [178]. A second molecule,
quercetin, was found to inhibit -catenin transcriptional activity when a constitutively
active -catenin mutant was transfected into cell lines. Quercetin inhibited the TCF
complex from binding to its DNA binding-site and inhibited -catenin-TCF association
as well as reduced -catenin nuclear translocation [179]. Another study found that
quercetin treatment resulted in reduced β-catenin transcriptional activity and reduced
colon cancer cell viability [180].

β-catenin and inflammation
There are conflicting reports regarding the role of -catenin in promoting or
inhibiting inflammation. On one hand, -catenin has been found to be necessary for the
production of anti-inflammatory molecules in lamina propria dendritic cells. Lamina
propria DCs from knockout mice had increased levels of mRNA encoding inflammatory
cytokines such as IL-23a and IL-6 and lower levels of anti-inflammatory IL-10.
Additionally, -catenin conditional knockout mice had lower frequencies of regulatory T
cells and higher frequencies of Th1 and Th17 cells in the lamina propria [181].
A few studies have shown that -catenin is involved in regulating inflammation
induced by Salmonella in epithelial cells. In one study, expression of constitutively
active -catenin decreased NFB’s ability to bind DNA. Activation of -catenin
signaling also inhibited IL-8 production induced by Salmonella [178]. In another study,
LiCl treatment, which inhibits GSK3 activity and leads to β-catenin accumulation,
resulted in reduction of Salmonella-induced IL-8 production. Moreover, cells expressing
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constitutively active -catenin had reduced NFB activity upon Salmonella infection
[182].
On the other hand, there are several reports that link -catenin expression with
increased inflammatory cytokine production in various cell types. In one study, treatment
of mycobacterial products (PPD)-reactive PBMC with neutralizing antibodies against
Wnt5a and its receptor, FZD5, resulted in reduced IL-12 production in response to PPD
and reduced IFN production by T cells [183]. Since Wnt5a plays a role in -catenin
signaling, these data indicate a role for -catenin in Th1 cytokine regulation. In another
study, -catenin was found to regulate IFN production by interacting with LRRFIP1, a
cytosolic nucleic acid sensor. In macrophages, this sensor promoted -catenin activation
by phosphorylating -catenin at the residue Ser552 upon infection with VSV, resulting in
increased IFN production through the interaction of -catenin with IRF3 and subsequent
binding to p300, leading to increased transcription of IFN[184]. Yet another study
reported that there is an increased expression of -catenin in microglia under
neuroinflammatory conditions, such as that found in Alzheimer's. Wnt3A stimulation of
microglia results in the expression of proinflammatory genes and the production of IL-6,
IL-12, and TNFα [185]. Interestingly, simultaneous activation with LPS led to
downregulation of the inflammatory response [186], suggesting that -catenin can either
upregulate or downregulate inflammation. Similarly, the activation of -catenin in APC/- mice resulted in the induction of a pro- and anti-inflammatory environment in the liver.
-catenin was found to directly induce expression of several genes including
Ccl24, Cxcl2, Cxcl10, Cxcl11, IL15, IL18, and Ikkβ, and was associated with NFB
activation. However, -catenin also upregulated chemokine-like chemotactic factor
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leukocyte cell–derived chemotaxin 2 (LECT2) gene, which was found to control the
intensity of the inflammation as well as the degree of tumor aggressiveness [187].
Overall, β-catenin’s role as an anti-inflammatory or pro-inflammatory agent
appears to be dependent on multiple parameters, including cell type, stimulus, and
experimental system being used. It can therefore be assumed that β-catenin is able to
modulate inflammation in either direction depending on the context/environment.
However, it is unknown what role β-catenin plays in the inflammatory cytokine
production that leads to Type I diabetes, which is the focus of this study.
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MATERIALS AND METHODS

Mice
C57BL/6Jg7, NOD/LtJ, and BDC2.5 NOD mice were purchased from the
Jackson Laboratory. All mice were maintained according to Institutional Animal Care
and Use Committee (IACUC) guidelines.

Generation of bone marrow-derived DC and human monocyte-derived DC
Bone marrow-derived dendritic cells (BMDC) were generated by culturing BM
cells for 12 days with 5 ng/mL granulocyte-monocyte colony stimulating factor (GMCSF; PeproTech) in complete media containing RPMI (Mediatech) supplemented with
1% 1M Hepes buffer (MP Biomedicals), 1% 100 mM sodium pyruvate, 1% 200 mM Lglutamine, 1% 10,000 IU/mL penicillin and 10,000 ug/mL streptomycin, 1% nonessential amino acids (Mediatech), 0.1% 50 mM 2-mercaptoethanol (Sigma-Aldrich),
and 10% fetal calf serum (FCS) (Hyclone). Monocytes were isolated from PBMC from
healthy and type 1 diabetic individuals (Research Blood Components) using CD14
microbeads and magnetic columns (Miltenyi) and were cultured for 8 days in the
presence of GM-CSF and IL-4 (PeproTech) in complete medium as described above.

Western Blot
Whole cell lysates were prepared using the lysis buffer and PBS+inhibitors
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recipes from the Universal Magnetic Co-IP Kit (ActiveMotif) for whole cell lysates.
Lysates were stored at -80ºC. Lysates were prepared for electrophoresis with NuPage
LDS Sample Buffer (Life Technologies) and NuPage Sample Reducing Agent (Life
Technologies). NuPage MES or MOPS SDS Running Buffer (Life Technologies) was
prepared with NuPage Antioxidant (Life Technologies). Samples were electrophoresed
using the NuPAGE system using 4-12% Bis-Tris gels. Protein was transferred onto
PVDF membrane using NuPage Transfer Buffer (Life Technologies) with 10% methanol
for 1.5-2 hours at 35V. Membranes were blocked in 5% non-fat dry milk in Tris-buffered
saline with Tween (TBST) prior to primary antibody incubation. Membranes were
incubated with primary antibody at a concentration of 1:1000 in 5% non-fat dry milk or
5% BSA in TBST overnight. Membranes were then incubated in anti-mouse or antirabbit HRP-linked secondary antibody (Cell Signaling) diluted in 5% non-fat dry milk for
1 hour before exposure. All washes were performed with TBST. Chemiluminescent
detection was performed using SuperSignal West Dura Chemiluminescent Substrate
(Thermo) or SuperSignal West Pico Chemiluminescent Substrate (Thermo). Membranes
were exposed using a Kodak Image Station 40000MM (Eastman Kodak) or an
ImageQuant LAS 4000 (GE Healthcare).

Confocal Microscopy
Cells were fixed with 4% paraformaldehyde in PBS for 1 hour at room
temperature, followed by permeabilization with 0.1% TritonX-100. Cells were then
labeled with anti--catenin primary antibody and AlexaFluor488 anti-rabbit secondary
antibody followed by DRAQ5 nuclear label (Alexis Biochemicals). Cells were
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visualized using an Olympus FV1000 confocal microscope.

Intracellular Labeling
Cells were incubated in Fc block, fixed in 4% paraformaldehyde at 37ºC,
permeabilized in 90% methanol, and labeled with anti--catenin antibodies followed by
AlexaFluor488 anti-rabbit secondary antibodies. Cells were then acquired and analyzed
using a FACScalibur (Becton Dickinson).

Antibodies
Antibodies used for Western blot, including antibodies against -catenin, Ecadherin, -actin, ubiquitin, phospho-Akt-308, phospho-Akt-473, pan Akt, phosphoPKA-197, total PKAc, phospho-GSK3-S9, total GSK3, phospho--catenin-S552,
phospho--catenin-S675, phospho-ERK1/2, total ERK1/2, phospho-p38, and total p-38
were all purchased from Cell Signaling. The anti--catenin antibodies used for confocal
and flow cytometry were also purchased from Cell Signaling. The AlexaFluor488 antirabbit antibody was purchased from Life Technologies.

Isolation of primary DC from organs
Spleens and Peyer’s patches were harvested, cut into small pieces, and then
incubated in collagenase VIII (Sigma) in Hank’s Buffered Saline Solution (HBSS) for 1
hour at 37º C. Tissue was then homogenized by syringe, filtered, and red blood cells in
the spleen were lysed using Tris ammonium chloride. Mesenteric lymph nodes were
harvested, pushed through a mesh filter with the end of a syringe plunger, and collected.
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Dendritic cells were then purified by labeling with CD11c magnetic beads and then
passed through a magnetic column. Cells were then surface-labeled with CD11c-APC
antibodies (Becton Dickinson) and labeled intracellulary for -catenin.

Transfection (siRNA and plasmids)
Mouse BMDC were transfected with 5 μg N-TARGET PLUS siRNA catenin beta
1.88kDa (cadherin associated protein) (DHARMACON RNA Technologies) and human
cells were transfected with 2 μg of this siRNA. For plasmid studies, 200 ng of pcDNA3S33Y -catenin (Addgene plasmid 19286) was used. Control cells were transfected with
siGLO RISC-Free siRNA or pcDNA3 wildtype -catenin plasmids (Addgene plasmid
16828). Cells were transfected using the AMAXA nucleofector system. Experiments
were performed on cells 72-96 hours following transfection with siRNA or 48-96 hours
following plasmid transfection.

-catenin Inhibitor Treatments
150,000 BMDC or human DC were pre-treated with 75 μM quercetin (Acros) or
12.5 μM ICG-001 (Dr. Michael Kahn) for 8 or 12 hours or 50 μM Wnt3 agonist for 30
minutes (Calbiochem) followed by stimulation with 1 μg/mL LPS for 24 hours.
Supernatants were collected after the 24-hour LPS treatment and cells were washed three
times before coculture as described below.

Coculture experiments
BMDC or human DC treated as described in the “Transfection” and “-catenin
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Inhibitor Treatments” sections were cocultured with mouse or human T cells. Mouse T
cells were prepared from spleen or lymph nodes from BDC2.5 NOD mice. Both types of
cells were magnetically labeled with anti-CD4 magnetic beads and then passed through a
CD4 T cell column (R&D). T cells were added to the cell culture along with 100 ng/mL
pancreatic peptide for the mouse experiments or 0.5 ug/mL human anti-CD3 antibody for
the human experiments. Supernatants were collected 48 hours later.

ELISA
Supernatants were collected and stored at -20ºC. Kits for IL-12 and IFN were
purchased from Biolegend and used according to the manufacturer’s instructions.

Delivery of -catenin inhibitors in vivo
For oral gavage delivery, a 25 mg/kg dose was give to each mouse three times a
week. For each mouse, 0.5 mg quercetin dihydrate (LKT labs) was dissolved in 10 uL
ethanol, filter sterilized and diluted 1:10 in sterile corn oil. For the vehicle, sterile ethanol
was added to sterile corn oil at a 1:10 dilution. 100 uL of these solutions were given to
each mouse.
For intraperitoneal delivery, a 5 mg/kg dose was given to each mouse twice a
week. For each mouse, 5 mg quercetin was diluted in 10 uL DMSO, filter sterilized, and
then diluted 1:1000 in water. For the vehicle, DMSO was diluted in water at a ratio of
1:1000. 200 uL of these solutions were injected into each mouse.
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Adoptive transfer of transfected DC
For the adoptive transfer experiments, 0.5 million BMDC/well were transfected
with 1 g of -catenin or control siRNA using the Amaxa system. One million treated or
control BMDC were then transferred intravenously to female 3 week-old NOD mice. To
determine diabetes incidence, urine glucose was tested beginning at 10 weeks of age.
Upon a positive test for urine glucose, blood glucose was taken and recorded. Mice were
considered to have diabetes after two consecutive blood glucose readings >300 mg/dL.

Urine and Blood Glucose Testing of NOD mice
Mice were tested once a week beginning at 10 weeks of age. Urine glucose was
first tested using Diastix (Bayer). Once the Diastix indicated that glucose was present in
the urine, blood glucose testing began. Blood glucose testing was performed on blood
from the tail using a human blood glucose monitor system from Walgreens. Blood
glucose was recorded and mice were considered to have diabetes after two consecutive
readings of > 600 mg/dL.

Real time RT-PCR
RNA was isolated from BMDC using an RNeasy Mini Kit (Qiagen). cDNA was
then prepared using the Quantitect Reverse Transcription Kit (Qiagen) and Quantitect
SYBR Green Kit (Qiagen). PCR was performed using a real time PCR machine (Applied
Biosystems).
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Coimmunoprecipitation
Coimmunoprecipitation experiments were performed using the Universal
Magnetic Co-IP Kit (ActiveMotif) for whole cell lysates. Pulldown antibodies
recognizing -catenin and E-cadherin were purchased from Cell Signaling.

Proteasomal Degradation Experiments
BMDC were pre-treated with a 50 μM dose of MG-132 (Tocris) for 12 hours.
The cells were washed and a 2 ug/mL dose of cycloheximide or DMSO vehicle was
added for 1, 2, 6, or 10 hours. Cells were washed and lysates prepared using the lysis
buffer from the Universal CoIP kit from ActiveMotif.

Akt/PKA Pathway Inhibitor and Activator Treatments
BMDC were treated with a 40 μM dose of the PKA inhibitor H89 (EMD
Millipore or LC Labs) or a 25 μM dose of the PI3K inhibitor LY294002 (Tocris) for 4
hours. Cells were then washed and lysed using the lysis buffer from the Universal CoIP
kit from ActiveMotif.

NFKB Activation Assay
Cells were treated with a 75 μM dose of quercetin (Acros) or a 12.5 μM dose of
ICG-001 (provided by Michael Kahn). Nuclear lysates were prepared using the Nuclear
Extract Kit (Active Motif). Nuclear lysates were then analyzed using the TransAm NFkB
Family Assay Kit (Active Motif).
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Statistical Analysis
All data were analyzed using the student’s t test. Statistical significance was
achieved when p<0.05.
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RESULTS

GOAL 1: CHARACTERIZING β-CATENIN EXRESSION AND ITS ROLE IN
PRO-INFLAMMATORY CYTOKINE PRODUCTION
Our lab has previously observed a novel defect in -catenin expression in BMDC
from adult NOD mice as compared to BMDC from diabetic-resistant adult B6.g7
mice. Therefore, we aimed to 1) characterize the expression of β-catenin in BMDC from
both NOD mice and human diabetic patients, in various NOD congenic strains, and in
primary DC from different organs and to 2) explore the correlation between -catenin
expression and pro-inflammatory cytokine production. To accomplish these goals, we
examined -catenin expression at various time points in disease progression, looking at
whole cell, nuclear, and cytoplasmic fractions by Western blot, FACS analysis, and
confocal microscopy. We also examined -catenin expression in Idd4 and Idd3/5 mice
through Western blot and in primary DC through FACS analysis. We used anti--catenin
siRNA treatment and -catenin inhibitors to inhibit expression and activity of -catenin
and measured resulting pro-inflammatory cytokine production and IFNγ induction in T
cells. Finally, we used -catenin plasmids and Wnt agonist treatment to induce -catenin
expression and activity in BMDC from non-diabetic mice and measured cytokine
production.
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In which cellular compartments is -catenin overexpressed in NOD BMDC at
different stages of disease?
Our lab has previously observed a defect in -catenin expression in BMDC from adult
NOD mice as compared to BMDC from diabetic-resistant adult B6.g7 mice. Diabetes
follows a predictable pattern of progression in NOD mice. At 3 weeks of age, periinsulitis, in which infiltrating cells surround the islets, is observed. By 6 weeks of age,
insulitis begins to develop. Beginning around 10 weeks of age, mice test positive for
high blood glucose, which reflects the destruction of their -islet cells, and are considered
to be diabetic. In order to examine the expression of -catenin at different time points
during disease progression, we performed Western blot, FACS analysis, and confocal
microscopy using bone marrow-derived DC (BMDC) from 3 weeks, 6 weeks, and 10+
weeks old mice.
Upon performing Western blot, we found that NOD BMDC express higher levels
of -catenin than B6.g7 BMDC at all disease stages examined (Figure 1A-F). We
confirmed our findings through FACS analysis and found a larger shift in -catenin
positive cells in the NOD BMDC compared to B6.g7 BMDC when compared to
unlabeled cells at all ages examined (Figure 1G-I).
To determine whether -catenin translocates to the nucleus where it can influence
gene transcription, we examined -catenin levels in the nuclei of NOD and B6.g7
BMDC. We found that NOD BMDC express higher levels of -catenin in the nucleus at
all disease stages (Figure 1 J-O), suggesting that high levels of -catenin may influence
the transcription of pathogenic proteins, such as IL-12, in type I diabetes.
Next, we performed confocal microscopy in order to examine the localization of
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-catenin in the cytoplasm and nucleus of NOD and B6.g7 BMDC. We found
statistically significant higher levels of -catenin in both the nucleus and cytoplasm of
NOD BMDC at both 3 and 6 weeks of age (Figure 1 P-U). Overall these data indicate
that -catenin is overexpressed in both the cytoplasm and nucleus of NOD BMDC during
the peri-insulitis, insulitis, and full-blown disease stages of diabetes development. This
suggests that -catenin is overexpressed even before disease onset and may be useful as a
prognostic marker. Additionally, the presence of higher levels of -catenin in the nuclei
of NOD BMDC indicates a possible role for this protein in transcription of other
important disease-associated genes.

Is -catenin overexpressed in primary dendritic cells from NOD mice?
Although we have found higher expression of -catenin in NOD BMDC, these
cells are cultured from bone marrow for a considerable length of time before use and
therefore are not necessarily representative of dendritic cells in vivo. To address this
issue, we examined -catenin levels in DC from the spleen, mesenteric lymph node, and
Peyer’s patches from both NOD and B6.g7 mice using flow cytometry. DC from each
organ were isolated using magnetic columns to separate the CD11c positive cells. Cells
were then labeled with CD11c-APC surface antibodies followed by intracellular labeling
with anti--catenin antibody and AlexaFluor488 antibody, and -catenin expression was
examined through FACS analysis. We found that DC from each organ expressed catenin, although at very low level, but there was very little difference in expression
between NOD and B6.g7 cells for any of the three organs examined (Figure 2 A-C).
It is possible that we could not see any difference because the expression of -
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catenin in DC from the chosen sites is very low. Other organs that are known for
containing -catenin-expressing DC such as lamina propria [181] should be tested in the
future and may allow us to distinguish the level of -catenin expression between NOD
and B6g7 DC.

Is -catenin overexpressed differentially in NOD and B6 congenic strains expressing
protective or disease-inducing loci from B10 or NOD mice, respectively?
Various sections of the NOD genome have been identified as conferring
susceptibility to diabetes. In our lab, we maintain B6Idd4 and NODIdd3/5 congenic
strains. Idd4 is a region identified on chromosome 11 which contains the candidate
diabetic-inducing genes platelet activating factor acetylhydrolase Ib1, nitric oxide
synthase-2, and CC chemokine genes [188]. The Idd4 mouse is a B6 mouse containing
the inserted Idd4 locus from NOD mouse but is resistant to diabetes development. Idd3
is found on chromosome 3 and contains the candidate gene for IL-2 [74], while Idd5 is
found on chromosome 1 and contains the candidate genes CTLA-4 and ICOS [189]. The
Idd3/5 mouse is an NOD mouse with the Idd3 and Idd5 regions from a B10 mouse
inserted into its genome which renders it diabetes-resistant. Although β-catenin is found
on the mouse chromosome 9, β-catenin may interact with other genes within these loci to
influence diabetes development. Therefore, we determined β-catenin expression in these
two strains of mice by Western blot (Figure3A-B). We found that BMDC from Idd3/5
overexpress β-catenin at levels similar to the NOD mouse, whereas BMDC from Idd4
mice have low levels as seen in the B6.g7 BMDC. Therefore, the overexpression of βcatenin is not linked to these three loci. As shown previously for other molecules
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associated with disease development, e.g., Iag7, a defect in β-catenin expression is not
sufficient to initiate diabetes in diabetes-resistant Idd3/5 mice. Instead β-catenin may be
one of several genes that contribute to diabetes risk.

Is there a correlation between -catenin levels in DC and pro-inflammatory cytokine
production in mice?
Inflammatory cytokines, especially IL-12 and IFN, have been shown to play
important roles in diabetes pathogenesis [112]. Additionally, several recent studies have
linked -catenin with inflammatory cytokine production [183-185, 187]. In light of these
studies, we investigated a role for -catenin overexpression in the pathogenic production
of IL-12 and IFN in NOD mice.
First, we explored the abilities of two -catenin inhibitors, quercetin and ICG001, to reduce pro-inflammatory cytokine production. Quercetin reduces the ability of
the -catenin/TCF complex to bind to its target DNA sequence and also reduces -catenin
nuclear translocation [179]. ICG-001, on the other hand, reduces the ability of-catenin
to bind to CBP [177]. Upon pre-treatment with either inhibitor, followed by LPS
stimulation of the NOD BMDC, we found that both inhibitors significantly reduced IL-12
production by the BMDC (Figure 4A and C). Next we cocultured the treated BMDC
with T cells from BDC2.5 mice. These mice contain T cells with a specific T cell receptor
that recognizes a pancreatic peptide [190]. Upon culture with antigen presenting cells
(the BMDC) and pancreatic peptide, these T cells differentiate into IFN-producing cells.
We found that treatment of the BMDC with either inhibitor also reduced IFN production
by these T cells (Figure 4B and D).
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Next, we knocked down -catenin expression by transfecting cells with anti-catenin siRNA and effectively reduced expression of -catenin (Figure 4E). Following
siRNA treatment, cells were stimulated with or without 1 μg/mL LPS and the
supernatants tested for IL-12. Knockdown of -catenin significantly lowered IL-12
production (Figure 4F). We finally incubated the treated cells with T cells from BDC2.5
mice. We found that BDC2.5 T cells incubated with anti--catenin siRNA-treated
BMDC produced significantly less IFN than T cells incubated with control siRNAtreated BMDC (Figure 4G). These results suggest that -catenin overexpression in NOD
BMDC does in fact play a role in the pathogenic production of inflammatory cytokines
that contribute to disease in these mice.
In a second set of experiments, we examined the ability of inducing
overexpression of -catenin in B6.g7 BMDC to increase pro-inflammatory cytokine
production. First, we treated the BMDC from B6.g7 mice with a Wnt agonist, which
effectively increased the levels of nuclear -catenin as compared to the vehicle control
treatment (Figure 5A). We found that this treatment also resulted in increased IL-12
production by the B6.g7 BMDC (Figure 5B) as well as increased IFN production by the
BDC2.5 T cells cocultured with the treated BMDC (Figure 5C).
Additionally, we transfected B6.g7 BMDC with either a -catenin plasmid
encoding a degradation-resistant form of -catenin or with a control plasmid.
Transfection with the -catenin plasmid effectively increased the level of nuclear catenin in these cells (Figure 5D). Using the same experimental system described above,
we found that treatment with this plasmid resulted in increased IL-12 production by the
B6.g7 BMDC (Figure 5E) as well as increased IFN production by the BDC2.5 T cells
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cocultured with these treated BMDC (Figure 5F). These data suggest that overexpressing
-catenin leads to increased IL-12 production. Overall, it appears that -catenin clearly
has a role in the regulation of pro-inflammatory cytokine production which may
contribute to Type I diabetes pathogenesis in NOD mice.

Is there a correlation between -catenin levels in DC and pro-inflammatory cytokine
production in humans?
Because we had found a correlation between overexpression of -catenin in NOD
BMDC and their ability to induce potential pathogenic cells, we wondered whether a
similar trend would also observed in cells from type 1 diabetic patients. First, we
established that mo-DC from T1D patients also express high levels of -catenin as
compared to cells from healthy controls through Western blot (Figure 6A). We confirmed
these results by FACS (Figure 6B) and confocal microscopy (Figure 6C). We then
examined the effect of knocking down -catenin expression and inhibiting -catenin
activity in these cells. First, we stimulated mo-DC from healthy and T1D donors with
LPS for 24 hours and measured levels of IL-12 production. Mo-DC from T1D patients
produced significantly higher levels of IL-12 as compared to cells from healthy donors
(Figure 6D). Next, we treated mo-DC with quercetin, the -catenin inhibitor, and
measured IL-12 production. As in mice, this treatment led to a reduction in IL-12
production (Figure 6E). Finally, we examined the effect of knocking down -catenin
expression with siRNA on pro-inflammatory cytokine expression. Similar to the results
found using mouse BMDC, we found that knocking down expression of -catenin led to
reduced IL-12 production by the moDC upon LPS stimulation for 24 hours (Figure 6F).
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Following LPS treatment, we added human T cells to the DC for 48 hours and measured
IFN production. We found that knockdown of -catenin in mo-DC also reduces IFN
production by the T cells (Figure 6G). These data therefore confirm in human cells the
observations made using NOD BMDC.
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Figure 1. NOD BMDC express higher levels of -catenin than B6.g7 BMDC in the
cytoplasm and nucleus and whole cell. Whole cell lysates were prepared from BMDC
from 3-week old (A), 6-week old (C), or adult (E) NOD or B6.g7 mice and Western blot
performed using anti--catenin and anti--actin antibodies. The band intensities were
quantified and expressed as fold change for 3-week old mice (B), 6-week old mice (D),
and adult mice (F). BMDC from 3-week old mice (G), 6-week old mice (H), and adult
mice (I) were labeled with anti--catenin primary antibody and AlexaFluor488 secondary
antibody and analyzed by FACS. Nuclear lysates were prepared from 3-week old (J), 6week old (L), or adult (N) NOD or B6.g7 BMDC and Western blot performed using anti-catenin and anti-LSD1 or anti-histone antibodies. The band intensities were quantified
and expressed as fold change for 3-week old (K), 6-week old mice (M), and adult mice
(O). BMDC from 3-week old (P), 6-week old (R), or adult (T) were labeled with anti-catenin primary antibodies and AlexaFluor488 secondary antibody and DRAQ5 nuclear
label and visualized by confocal microscopy. Relative intensities of -catenin are shown
for the nucleus and cytoplasm of BMDC from adult mice (Q), 6-week old mice (S), and
3-week old mice (U). * indicates p<0.05; *** indicates p<0.0001. Data are
representative of two or more independent experiments.
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Figure 2: Expression of -catenin by primary DC from NOD and B6.g7 lymphoid
organs. DC were isolated from various organs, treated with Fc block, surface labeled
using anti-CD11c-APC conjugated antibodies and labeled intracellularly using anti-catenin primary antibodies or IgG isotype control antibodies and AlexaFluor488
secondary antibodies. Cells were analyzed through FACS. The histograms show the catenin-labeled cells in black and the isotype control-labeled cells in gray for each organ
in B6.g7 (A-C) and NOD (D-F). The overlay of --catenin labeled NOD cells in black
over --catenin labeled B6.g7 cells in gray is shown for the MLN (G), Peyer’s patches
(H), and spleen (I).
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Figure 4. Inhibiting the activity of or knocking down expression of -catenin in NOD
BMDC leads to reduced IL-12 production and IFN induction of T cells. NOD
BMDC were pretreated with 75 μM quercetin or vehicle (A-B) or 12.5 μM ICG-001 or
vehicle (C-D) for 12 hours, washed, and stimulated with 1 μg/mL LPS for 24 hours. The
supernatants were collected and the presence of IL-12 was detected by ELISA (A, C).
Quercetin-treated BMDC (B) or ICG-001-treated BMDC (D) were then washed and
cocultured with 1x105 T cells from BDC2.5 mice for 48 hours along with 100 ng/mL of
pancreatic peptide. Supernatants were collected and tested for the presence of IFN by
ELISA (B, D). NOD BMDC were transfected with 5 ng of -catenin siRNA or control
siRNA and 96 hours later lysed. Western blot was performed with anti--catenin and actin antibodies and the bands quantified by densitometry analysis (E). Transfected cells
were treated with or without 1 μg/mL of LPS for 24 hours. Supernatants were collected
and tested for the presence of IL-12 through ELISA (F). Transfected and LPS-treated
cells were cultured with BDC2.5 T cells and 100 ng/mL pancreatic peptide for 48 hours.
Supernatants were collected and tested for the presence of IFN through ELISA (G).
*indicates p<0.005.
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Figure 5: Increasing the activity or expression of -catenin in B6.g7 BMDC leads to
increased IL-12 production and IFN induction of T cells. B6.g7 BMDC were treated
with 50 μM Wnt agonist. Nuclear lysis was performed followed by Western blot using
anti--catenin and anti-histone antibodies. The band intensities were quantified and
expressed as relative intensities (A). Following treatment, cells were washed and treated
with 1 μg/mL LPS for 24 hours. Supernatants were collected and tested for the presence
of IL-12 by ELISA (B). BMDC were then washed and cocultured with 1x105 T cells
from BDC2.5 mice for 48 hours along with 100 ng/mL of pancreatic peptide.
Supernatants were collected and tested for the presence of IFN by ELISA (C).
B6.g7 BMDC were transfected with -catenin or control plasmid, lysed, and subjected to
Western blot using anti--catenin and anti--actin antibodies. The band intensities were
quantified and expressed as relative intensities (D). Following transfection, cells were
treated with 1 μg/mL LPS for 24 hours. Supernatants were collected and tested for the
presence of IL-12 by ELISA (E). BMDC were then washed and cocultured with 1x105 T
cells from BDC2.5 mice for 48 hours along with 100 ng/mL of pancreatic peptide.
Supernatants were collected and tested for the presence of IFN by ELISA (F). *
indicates p<0.005.
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Figure 6: Human monocyte-derived DC express higher levels of -catenin than
moDC from non-diabetic donors, and inhibiting the activity of -catenin in human
monocyte-derived DC leads to reduced pro-inflammatory cytokine production.
Western blot was performed on whole cell lysates from DC from 10 different patients and
healthy donors using anti--catenin and anti--actin antibodies. The densities of the
bands were quantified and expressed as a ratio for each sample (A). moDC from diabetic
human patients were labeled with isotype control or anti-β-catenin antibody followed by
secondary antibodies and analyzed by FACS (B) or labeled with nuclear dye and
analyzed by confocal microscopy (C). moDC from healthy donors and diabetic patients
were stimulated with or without LPS for 24 hours and the supernatants collected and
tested for the presence of IL-12 by ELISA (D). moDC from diabetic patients were pretreated with quercetin for 12 hours followed by LPS treatment for 24 hours. Supernatants
were collected and tested for the presence of IL-12 by ELISA (E). moDC from diabetic
patients were treated with anti--catenin or control siRNA, followed by stimulation with
or without LPS for 24 hours. Supernatants were collected and tested for the presence of
IL-12 by ELISA (F). siRNA-treated cells were then cocultured with human T cells for 48
hours. Supernatants were collected and tested for the presence of IFN by ELISA (G). *
indicates p=0.05; ** indicates p<0.0387; *** indicates p<0.005.
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GOAL 2: PREVENTING AND/OR TREATING TYPE I DIABETES BY
REDUCING THE INFLAMMATORY ENVIRONMENT IN VIVO
Because pathogenic cytokine production by NOD BMDC can be reduced with βcatenin inhibitors or siRNA, as outlined in Goal 1, we sought to determine the ability of
1) the β-catenin inhibitor, quercetin, to reduce disease incidence, prolong survival, and
reduce inflammation in NOD mice and 2) β-catenin siRNA-treated BMDC transfer to
reduce disease incidence and prolong survival. Therefore, we performed a series of in
vivo experiments in which quercetin was delivered for various amounts of time and
through different routes.

Can direct delivery of -catenin inhibitors reduce inflammation and inhibit diabetes
development and mortality in vivo?
In light of our in vitro data showing that β-catenin is overexpressed in NOD
BMDC, we sought to examine the effect of inhibiting β-catenin on disease incidence,
survival, and pro-inflammatory cytokine production in vivo. First, we examined the effect
of a -catenin inhibitor, quercetin, on disease incidence and survival in NOD mice.
Although quercetin inhibits several molecules, it has been found to inhibit -catenin
nuclear translocation as well as -catenin transcriptional activity [179, 180]. Therefore,
we delivered quercetin or vehicle both orally and intraperitoneally to NOD mice. In the
first of two experiments, a 25 mg/kg dose of quercetin or vehicle was
delivered three times a week orally beginning at 3 weeks of age (Figure 7A and B).
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Treatment continued until sacrifice, which occurred after two high blood glucose
readings (>300 mg/dL). In the second experiment, mice were allowed to die naturally
(Figure 7C and D). For both experiments, it appears that incidence may be slightly
increased and survival slightly decreased with quercetin treatment as compared to vehicle
treatment in each experiment, suggesting that oral delivery of quercetin is ineffective at
preventing disease.
Because it appears that oral quercetin treatment had little effect on disease
incidence or survival in NOD mice, next we designed an experiment in which a 5 mg/kg
dose of quercetin or vehicle was injected intraperitoneally two times a week for 18 weeks
based on a previous study showing that this dosage was effective at reducing
proliferation in a breast cancer model when used in combination with other polyphenols
[191]. Mice were allowed to die naturally. In the first of two experiments, treatment
significantly delayed disease incidence and slightly increased survival (Figure 8A and B).
Additionally, it appeared that incidence in the quercetin-treated group increased sharply
upon discontinuation of the treatment at 21 weeks of age. However, in the second
experiment, quercetin treatment had no effect on incidence or survival (Figure 8C and D).
We also performed another experiment in which quercetin treatment continued for the life
of each mouse (Figure 9A and B). However, lifetime treatment was not more effective
than 18 week treatment in reducing incidence or increasing survival rates. There is a
possibility that the discrepancy between the data from the different experiments is due to
the potential inactivation of quercetin between the first intraperitoneal experiment and the
two other experiments which were started 5 months later. To ease the solubilization of
quercetin, some quantity was kept at 30ºC possibly for the entire period between the
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experiments. However, storage at this temperature is not recommended for more than
afew weeks. We are currently performing experiments in which fresh quercetin is used to
prepare the treatments over the course of the experiment.
We also examined if intraperitoneal injection of quercetin into NOD mice had an
impact on the in vivo production of IFN. Therefore, we treated a separate group of NOD
mice with quercetin intraperitoneally twice a week starting at 3 weeks of age and
harvested the spleens of mice at 14 weeks of age, after approximately 10 weeks of
treatment. Two quercetin-treated and two vehicle-treated mice were used, one of which
had tested positive for high blood glucose and one of which was healthy in each group.
Spleen cells were stimulated with anti-CD3 or left untreated and supernatants collected
and analyzed for IFNγ production through ELISA. After both 72 and 96 hours of
stimulation, the spleen cells from the quercetin-treated mice produced much less IFNγ
than spleen cells from vehicle-treated mice regardless of disease state (Figure 8E and F).
This suggests that quercetin treatment does reduce the pathogenic inflammatory
environment that contributes to Type I diabetes development in NOD mice. However,
systemic reduction of IFNγ may not be a good indication of disease status, suggesting
that pancreatic lymph nodes and pancreas may be better organs to test. Other disease
mechanisms are most likely still at play.

Can -catenin siRNA treated-BMDC transfer reduce disease incidence and
mortality in vivo?
We have found that downregulating -catenin expression with siRNA treatment is
effective in reducing IL-12 production in BMDC and subsequent IFN induction by T
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cells co-cultured with the siRNA-treated BMDC in vitro. Therefore, we hypothesized
that adoptive transfer of DC treated with anti--catenin siRNA would be effective in
reducing disease incidence and/or increasing survival by reducing the pro-inflammatory
environment that contributes to Type I diabetes.
We found that a single transfer of BMDC in which -catenin expression had been
knocked down resulted in delayed disease incidence and increased survival as compared
to transfer of control siRNA-treated BMDC (Figure 10A and B). This suggests that even
though the BMDC do not persist in the mouse, this reduction in -catenin may be enough
to reduce the inflammatory environment contributing to Type I diabetes and impact
disease and/or induce long-term tolerance.
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Figure 7. Oral gavage in vivo delivery of quercetin does not delay disease incidence
or increase survival in NOD mice. In A) and B) female NOD mice were orally gavaged
with a 25 mg/kg dose of quercetin in oil or vehicle three times a week beginning at three
weeks of age and continuing throughout the lifespan of each mouse. Urine glucose was
tested beginning at 10 weeks of age. Mice were considered to have diabetes after two
consecutive high (>300 mg/dL) blood glucose readings and were sacrificed. Incidence
A) and survival B) are shown. In C) and D), mice were orally treated with quercetin or
vehicle beginning at three weeks of age and continuing for 18 consecutive weeks. Mice
were allowed to die naturally. Testing was performed as in A) and B). Incidence C) and
survival D) are shown. n=5 for both experiments.
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Figure 8. Intraperitoneal injection of quercetin may delay disease incidence and
increase survival by reducing the pathogenic inflammatory environment that
contributes to Type I diabetes. Female NOD mice (n=5) were injected intraperitoneally
with a 5 mg/kg dose of quercetin or vehicle two times a week beginning at 3 weeks of
age and continuing for 18 consecutive weeks. Urine glucose was tested beginning at 10
weeks of age. Mice were considered to have diabetes after two consecutive high (>300
mg/dL) blood glucose readings. For the first experiment, incidence is shown in A) and
survival in B). For the second experiment, incidence is shown in C) and survival in D).
Spleens from a third group of treated mice were harvested after 10 weeks of treatment
and cells were stimulated with a 0.5 μg/mL dose of anti-CD3 or no stimulation. Two
quercetin-treated and two vehicle-treated mice were used. Supernatants were collected at
72 hours E) and 96 hours F). Supernatants were probed for IFN through ELISA.
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Figure 9. Lifetime intraperitoneal treatment with quercetin does not increase
survival or reduce disease incidence as compared to 18-week treatment. Female
NOD mice were injected intraperitoneally with a 5 mg/kg dose of quercetin or vehicle
two times a week beginning at 3 weeks of age and continuing for the duration of the
experiment (n=5). Urine glucose was tested beginning at 10 weeks of age. Mice were
considered to have diabetes after two consecutive high (>300 mg/dL) blood glucose
readings. Incidence is shown in A) and survival in B).
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Figure 10. Adoptive transfer of -catenin siRNA-treated DC reduces disease
incidence and slightly increases survival. A) BMDC were transfected with -catenin
siRNA or control siRNA and one million cells were then transferred intravenously to
female 3 week-old NOD mice (n=5). Urine glucose was tested beginning at 10 weeks of
age. Mice were considered to have diabetes after two consecutive high (>300 mg/dL)
blood glucose readings. Incidence is shown in A) and survival in B).

62

GOAL 3: EXPLORING THE MECHANISMS BY WHICH -CATENIN
ACCUMULATES AND INFLUENCES PRO-INFLAMMATORY
CYTOKINE PRODUCTION
In Goal 1, we demonstrated that NOD BMDC overexpress β-catenin and this
overexpression correlates with increased pro-inflammatory cytokine production.
Therefore, in this study, we aimed to 1) determine the mechanism of accumulation of βcatenin in NOD BMDC and 2) determine the mechanism by which β-catenin infuences
pro-inflammatory cytokine production. We performed a series of experiments to
determine defects that might lead to accumulation including transcription rate,
interactions between β-catenin and E-cadherin, proteasomal degradation and
ubiquitination, GSK3β phosphorylation, and stabilizing phosphorylations of β-catenin.
Finally, we examined differences in MAPK pathway activation and NFκB activation as
potential mechanisms leading to increased pro-inflammatory cytokine production.

1. Why does β-catenin accumulate at high levels in NOD BMDC?
Due to the complexity of β-catenin regulation within the cell, there are several
possible mechanisms by which β-catenin may accumulate in the cytoplasm of BMDC
from NOD mice. These mechanisms include increased transcription, defective
sequestration by E-cadherin, defective proteasomal degradation of β-catenin, defective
ubiquitination of β-catenin, and defective phosphorylation of β-catenin. The figure
shown on page 26 of the introduction provides an excellent overview of the various
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points at which β-catenin expression is regulated within the cell [159]. In this study, we
examined each of these mechanisms by comparing NOD BMDC to B6.g7 BMDC.

1.1 Does an elevated level of β-catenin transcription play a role in -catenin
accumulation of β-catenin in NOD BMDC?
Because transcriptional rates can vary and lead to differences in protein
expression, we first examined defects in transcription in NOD BMDC. To identify defects
in transcription of β-catenin mRNA, we compared mRNA levels between NOD BMDC
and B6.g7 BMDC by real time RT-PCR. In two independent experiments, there was no
difference in β-catenin mRNA levels observed between the NOD and B6.g7 cells (Figure
11A). This indicates that β-catenin accumulation is the result of some other mechanism
independent of transcriptional rate.

1.2 Does defective sequestration of β-catenin by E-cadherin play a role in
accumulation of β-catenin in NOD BMDC?
β-catenin plays an important role in cell adhesions due to its ability to complex
with E-cadherin at the cell membrane. The interaction between these two proteins helps
regulate -catenin signaling in the cell: several studies suggest that E-cadherin recruits catenin to the cell membrane and keeps it from accumulating in the nucleus where it can
induce transcription [134, 135]. Defects in the interaction between β-catenin and Ecadherin could therefore result in the accumulation of β-catenin in NOD BMDC.
We first examined the expression of these two proteins in BMDC by Western blot
using anti-β-catenin and anti-E-cadherin antibodies. We observed that NOD BMDC
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express not only more β-catenin, but more E-cadherin as well (Figures 11B and C).
Therefore, we chose to perform a co-immunoprecipitation experiment in which protein
from whole cell lysates was pulled down with either a β-catenin antibody or an Ecadherin antibody. In these coimmunoprecipitation experiments, the ratio of E-cadherin
to β-catenin was not significantly different in the two cell types when using either a βcatenin or E-cadherin precipitating antibody (Figure 11D-G). This data indicates that
there is no difference in the interaction between E-cadherin and β-catenin in NOD
BMDC compared to B6.g7 BMDC. Therefore, excess accumulation of β-catenin in the
NOD BMDC cannot be attributed to defective sequestration at the cell membrane.

1.3 Does defective proteasomal degradation or ubiquitination play a role in
accumulation of β-catenin in NOD BMDC?
β-catenin is a protein that is prone to degradation and for this reason difficult to
study in normal primary cells. In the cytoplasm, β-catenin forms a destruction complex
with several other proteins including axin, APC, and GSK3. CK1 phosphorylates catenin at serine 45 [120, 129] which primes the-catenin molecule for phosphorylation
by GSK3 on Ser33 and 37 and Thr41 [142]. Once -catenin is phosphorylated by
GSK3, it is ubiquitinated and degraded by the proteasome [130]. Decreases in β-catenin
ubiquitination and proteasomal degradation could therefore explain the accumulation of
cytoplasmic β-catenin in NOD BMDC.
We assessed degradation rate of β-catenin in NOD and B6.g7 cells BMDC upon
overnight pre-treatment with MG-132, a proteasome inhibitor. This treatment, by
inhibiting proteasomal degradation, results in accumulation of β-catenin, allowing for
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easier detection and quantification of this protein in the B6.g7 cells, which as we have
shown do not express much β-catenin. After MG-132 treatment, the cells were washed
and cycloheximide, a protein synthesis inhibitor, or the corresponding vehicle control was
added for various time-points: 1, 2, 6, or 10 hours. Cells were lysed and the lysates
probed with anti-β-catenin antibodies (Figure 11H). The amount of β-catenin left at each
time point was calculated as a percentage of the original amount for each cell type,
plotted on a logarithmic plot, and linear regression performed. The T1/2 value was
calculated using the equation of the line by solving for time when 50% of β-catenin was
left (Figure 11I and J). It appears that degradation rate of β-catenin is much slower in
B6g7 BMDC, in which the T1/2 value was 6.2 hours with cycloheximide and 6.5 hours
with vehicle only, than in NOD, in which the T1/2 value was 3.3 hours with cycloheximide
and 5.3 hours with vehicle only. The quicker degradation of β-catenin in NOD BMDC is
puzzling, but may be the result of differences in the activity of other degradation
pathways, such as the lysosomal pathway. Despite this unexpected result, these data
suggest that differences in proteasomal degradation rate do not play a role in the
accumulation of β-catenin in NOD BMDC.
We also determined if there were differences in the amount of ubiquitinated catenin as a proportion of total β-catenin in NOD and B6.g7 cells. First we quantitatively
analyzed the expression of ubiquitinated β-catenin observed in Figure 1H in the previous
experiment upon MG132 treatment. Ubiquitination will result in bands of heavier
molecular weight due to attachment of ubiquitin molecules (approximately 8.5 kDa).
Previous studies have identified this higher molecular weight β-catenin as monoubiquitinated β-catenin that accumulated in the presence of the ubiquitin ligase β-TrCP or
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proteasome inhibitors [192, 193]. Additionally, we only see this higher molecular weight
band following MG-132 treatment, suggesting that this band represents ubiquitinated βcatenin as opposed to phosphorylated β-catenin or another protein. However, we cannot
definitively rule out this heavier band as representing phosphorylated β-catenin unless we
treated the cells with phosphatase in the experimental setup. We found that the amount of
mono-ubiquitinated β-catenin was very similar between B6.g7 and NOD for each time
point examined (Figure 11K).

1.4 Does defective phosphorylation of β-catenin play a role in accumulation of catenin in NOD BMDC?
β-catenin degradation and stabilization are regulated by its phosphorylation at
various residues: phosphorylation at some residues leads to destabilization of β-catenin,
while phosphorylation at other residues leads to its stabilization as illustrated in the figure
on page 26. GSK3phosphorylation of β-catenin at Ser33, Ser37, and Thr41 results in
its ubiquitination [142] and degradation by the proteasome [130]. In contrast, upon
phosphorylation of β-catenin at Ser552 by PKA [156] or Akt [150] or at Ser675 by PKA
[158], β-catenin degradation is inhibited allowing β-catenin to accumulate in the
cytoplasm and nucleus of cells. In light of these data, we hypothesized that lower
destabilizing phosphorylation, or higher stabilizing phosphorylation may be responsible
for the accumulation of β-catenin in NOD BMDC.
Lower levels of GSK3 activity in NOD BMDC could lead to lower -catenin
degradation and its accumulation. Because GSK3β is known to phosphorylate -catenin
at residues Ser33, Ser37, and Thr41, which marks -catenin for ubiquitination and
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proteasomal degradation [130, 142], we hypothesized that downregulation of GSK3β
activity may be responsible for -catenin accumulation in NOD BMDC. We examined
levels of phosphorylation of GSK3 at serine Ser9, an inhibitory phosphorylation [149].
We hypothesized GSK3 may be phosphorylated at higher levels at this residue in NOD
BMDC resulting in reduced activity and reduced -catenin degradation [149]. It appears
that GSK3 from B6.g7 BMDC is phosphorylated at slightly higher levels than in NOD
BMDC, although the differences are very small (Figure 12A and B). These data
suggests that GSK3 activity is normal in NOD BMDC and thereby does not lead to
reduced degradation of -catenin in NOD BMDC and does not contribute to -catenin
accumulation, confirming the previous degradation experiments (Figure 11H).
Accumulation of -catenin in NOD BMDC must therefore occur through some other
mechanism.
Since decreased destabilizing phosphorylation are not responsible for
accumulation of β-catenin, increases in the phosphorylation level of β-catenin at residues
Ser552 and Ser675 may be responsible for the stabilization and accumulation of β-catenin
in NOD BMDC. Western blot analysis of NOD and B6.g7 BMDC using anti-phospho-βcatenin antibodies for Ser675 (Figure 12C-F) and Ser552 (Figure 12G-J) shows that there
is a greater proportion of -catenin phosphorylated at these two residues as well as a
greater amount of phosphorylated -catenin as a proportion of total protein in NOD
BMDC as compared to B6.g7 BMDC. This suggests that these stabilizing
phosphorylations may be partly or wholly responsible for the accumulation of -catenin
in NOD BMDC. We therefore examined the impact of inhibiting Akt and PKA on βcatenin phosphorylation and expression. NOD BMDC cells were treated with a 25 μM
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dose of LY294002, a PI3K inhibitor, a 40 μM dose of the PKA inhibitor H89 or vehicle
for four hours. Cell lysates were prepared and Western blot was performed using anti-βcatenin and anti-β-actin antibodies (Figure 12K). Both of these inhibitors resulted in
decreased phosphorylation of -catenin at Ser552 (Figure 12L) and -catenin expression
(Figure 12M) suggesting that Akt and PKA may stabilize-catenin and lead to its
accumulation in NOD BMDC.
Because Akt and PKA appear to mediate accumulation of -catenin in NOD
BMDC we wondered whether expression and/or activity of Akt and PKA is higher in
NOD BMDC. First we examined expression levels of total PKA and total Akt in NOD
and B6.g7 BMDC. Western blot analysis using anti-PKA and anti-Akt antibodies showed
no difference in expression for either PKA (Figure 13A and B) or Akt (Figure 13C and D)
between NOD and B6.g7 BMDC. Next, we assessed the level of activation of PKA and
Akt. We measured Akt phosphorylation at Thr308 and Thr473, two known activating
residues, after 30 minutes of stimulation with a 1 μg/mL dose of LPS. For Akt Thr308,
we found higher levels of phosphorylation in unstimulated NOD BMDC in 2 out of 3
experiments (Figure 13 E and F). Upon LPS stimulation, we found more
phosphorylation in B6.g7 BMDC in 3 out of 4 experiments (Figure 13 G and H).
Therefore it appears that this residue is constitutively phosphorylated at higher levels in
NOD BMDC but upon stimulation, it is phosphorylated and activated at higher levels in
B6.g7 BMDC. This higher level of phosporylation under non-stimulation conditions may
explain the higher levels of phosphorylated -catenin in NOD BMDC. In contrast, we
found higher levels of phosphorylation of Akt at Thr473 in B6.g7 BMDC (Figure 13I and
J) with and without LPS stimulation, in most of the experiments. Therefore, it is unlikely
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that increased activation of Akt through phosphorylation at Thr473 is responsible for the
increased phosphorylation of -catenin at Ser552 in NOD BMDC. We finally examined
levels of phosphorylation of PKA at Thr197, a residue that has been associated with
optimal enzymatic activity [153, 154]. However, it appeared that PKA was
phosphorylated at similar levels in B6.g7 and NOD BMDC (Figure 13 K and L).

2. Why does β-catenin accumulate in the nucleus of NOD BMDC but not B6.g7
BMDC?
There are several possible mechanisms by which β-catenin may accumulate in the
nucleus of the BMDC from NOD mice. These include defects in sumoylation, defects in
phosphorylation by Pyk2, or simply defects in degradation that allow excess β-catenin to
accumulate and translocate to the nucleus.

2.1 Does defective sumoylation play a role in nuclear accumulation of β-catenin in
NOD BMDC?
Sumoylation of proteins has several biological functions: repression of
transcriptional activity, such as in the case of sumoylation of p300, a transcriptional
coactivator of β-catenin; activation of transcriptional activity, such as in the case of Tcf-4,
another transcriptional coactivator of β-catenin; ordering of chromatin structure; DNA
repair; nuclear transport and retention; and inhibition of NFκB-mediated inflammatory
responses [194].
Because-catenin contains candidate sumoylation sites and accumulates at higher
levels in the nucleus of NOD BMDC, we hypothesized that differences in sumoylation of
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β-catenin may contribute to the differences observed in nuclear β-catenin levels.
Therefore, we performed coimmunoprecipitation experiments to examine the amount of
sumoylated β-catenin in NOD and B6.g7 BMDC. However, we were unable to detect
any sumoylated β-catenin in any of the experiments performed (data not shown). This
may be due to several factors: proteins are typically sumoylated at low levels, and
desumoylation is usually rapid. Therefore, it is difficult to conclude anything other than
sumoylation of β-catenin may not be occurring and/or there may be undetectable
differences in sumoylation of β-catenin in NOD and B6.g7 BMDC.

2.2 Does defective expression of Pyk2 or defective phosphorylation of β-catenin by
Pyk2 play a role in nuclear accumulation of β-catenin in NOD BMDC?
It has been shown that Pyk, a tyrosine kinase, phosphorylates β-catenin at tyrosine
residues [195, 196]. This phosphorylation is associated with decreased attachment to Ecadherin and increased stability and nuclear translocation of β-catenin [197]. Therefore,
we examined Pyk2 expression, Pyk2 activity, and the ability of Pyk2 to interact with βcatenin in NOD and B6.g7 BMDC.
Upon probing the cytoplasmic fraction after cell lysis, we were unable to detect
Pyk2 expression in the cytoplasm of either B6.g7 or NOD BMDC (data not shown).
Additionally, following coimmunoprecipitation with an anti-β-catenin antibody, we did
not detect any Pyk2 interaction with β-catenin (data not shown). Finally, we found that
treatment with AG17, a Pyk2 inhibitor, did not result in a decrease in β-catenin nuclear
translocation when compared to vehicle-treated cells (data not shown). Although we can
not rule out that the experimental conditions were not optimal, these data suggest that
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Pyk2 phosphorylation of β-catenin may not be an important contributor to β-catenin
nuclear translocation in NOD BMDC.

3. What are the mechanisms by which β-catenin induces pro-inflammatory cytokine
production?
It is well-established that NOD dendritic cells produce aberrant levels of proinflammatory cytokines [119, 121, 198]. Additionally, we have established that β-catenin
is overexpressed in NOD BMDC as compared to B6.g7 BMDC. Therefore, we examined
several mechanisms by which β-catenin might directly influence the level of proinflammatory cytokine production in BMDC. The mechanisms explored include an
interaction between β-catenin and the MAPK pathway and an interaction between βcatenin and the NFκB pathway.

3.1 Does β-catenin activate the MAPK pathway to induce pro-inflammatory
cytokine production?
MAP kinases are serine/threonine kinases that phosphorylate transcription factors
in order to modulate gene expression. There are three major groups of MAP kinases:
JNKs, ERKs, and p38 MAP kinases [199]. There is crosstalk between these pathways
and several other signaling pathways. For example, Akt and PI3K can abnormally
activate the ERK pathway in cancer [200]. It has also been shown that there is crosstalk
between the MAPK pathway and the β-catenin signaling pathway. In one study ERK was
found to be activated by Hepatitis B viral infection. This activation resulted in the
inhibitory phosphorylation of GSK3β at Ser9 and subsequent accumulation of β-catenin
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[201].
Interestingly, the MAPK pathways have been shown to be involved in the
production of IL-12, although the data is contradictory. Depending on the cell type,
stimulation, and experimental system being used, ERK and p38 have a direct relationship
with IL-12 production in which stimulation of these pathways increases production or
inhibition decreases production [202-204], or an inverse relationship with IL-12
production in which stimulation decreases production and inhibition increases production
[205-207]. Yet another set of studies demonstrate that ERK and p38 may have reciprocal
functions in which activation of ERK results in suppression of the pro-inflammatory
response while activation of p38 results in increased inflammation [150, 208].
In light of these data, we hypothesized that there may be crosstalk between βcatenin signaling and the MAPK pathway in BMDC. β-catenin overexpression may lead
to increased ERK or p38 activity in NOD BMDC, resulting in altered pro-inflammatory
cytokine production. In order to test this hypothesis, we stimulated NOD and B6.g7
BMDC with a 1 g/mL dose of LPS for various time points and examined the resulting
p38 and ERK1/2 activation. As shown in Figure 14, there was no statistically significant
difference in phosphorylation of ERK at p42/p44 and in NOD cells compared to B6g7
cells after LPS stimulation. Additionally, there were no differences in p38 activation.
Therefore, the excess pro-inflammatory cytokine production observed in NOD BMDC
does not appear to be the result of defects in MAPK activity.
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3.2 Does β-catenin interact with the NFκB pathway to induce pro-inflammatory
cytokine production?
It has been well-established that activation of the NFκB pathway induces proinflammatory cytokine production, including the production of IL-12 [209, 210]. The
NFκB family includes RelA (p65), RelB, and c-Rel, and NFkB-1 (composed of p105 and
p50) and NFκB-2 (composed of p100 and p52). NFκB proteins are usually rendered
transcriptionally inactive in the cytoplasm by IκB proteins in the cytoplasm. Upon
phosphorylation by IKK proteins, the IκB proteins undergo proteasomal degradation,
thereby releasing the NFκB proteins, allowing for them to become transcriptionally active
[211]. Additionally, it has been shown that DNA binding by NFκB is higher in NOD
BMDC than BMDC from control mice. Moreover, LPS stimulation also resulted in
increased NFκB nuclear translocation rates in NOD BMDC than in control cells [121].
Interestingly, β-catenin can physically interact with NFκB. One study found that upon
association of the two proteins, NFκB binding to DNA and target gene expression was
reduced in human colon and breast cancer cells [212].
In light of these data, we hypothesized that a defect in the interaction between the
β-catenin and NFκB pathways in NOD BMDC was responsible for the excess IL-12
production by these cells. To test this hypothesis, we treated NOD BMDC with two βcatenin inhibitors, ICG-001 and quercetin, at 0, 10, 30, and 60 minutes and measured the
level of NFκB p50 and p65 activation by ELISA (Figure 15). We found that both
inhibitors reduced the amount of activated p50 and p65 as compared to the vehicle
treatment for all time points. This suggests that the β-catenin pathway interacts with the
NFκB pathway, and this interaction may influence pro-inflammatory cytokine expression
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in NOD BMDC.
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Figure 11. Lack of difference in -catenin mRNA levels, in the interaction between
β-catenin and E-cadherin, and in the degradation rate and ubiquitintion of βcatenin between B6.g7 and NOD BMDC. RNA was isolated from B6.g7 and NOD
BMDC and real time rt-PCR was performed to determine the amounts of β-catenin
mRNA relative to the amount of mRNA for the housekeeping gene, GAPDH. The data
includes two independent experiments, one of which included two separate samples (A).
NOD and B6.g7 BMDC were lysed, and Western blot was performed using anti-Ecadherin and anti-β-catenin antibodies (B). The fold change of E-cadherin to β-catenin is
shown (C). Coimmunoprecipitation was performed with anti-E-cadherin (D) or anti-βcatenin (F) antibodies to pull down protein from the cell lysate from NOD or B6.g7
BMDC. Western blot was then performed using anti-β-catenin and anti-E-cadherin
antibodies. The average ratios of β-catenin to E-cadherin or E-cadherin to β-catenin for 3
experiments after using an anti-E-cadherin pulldown (E) or anti-β-catenin (G) pulldown
antibody, respectively, are shown. Cells were treated with 50 uM of MG132 for 12
hours, washed and treated with 2 ug/mL of cycloheximide or vehicle then lysed. Western
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blot was performed on cell lysates with anti-β-catenin and anti-β-actin antibodies (H).
The percentages of β-catenin remaining at each time point were plotted on a logarithmic
scale and linear regression performed for vehicle (I) and cycloheximide treatments (J).
The equations of the lines are shown in blue (B6.g7) and red (NOD). The T1/2 values are
also displayed on the graphs. The fold change for mono-ubiquitinated β-catenin as a ratio
of non-mono-ubiquitinated-β-catenin is shown (K). Data are representative of two or
more independent experiments.
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Figure 12: β-catenin accumulates in NOD BMDC through stabilizing
phosphorylations through an Akt and PKA-dependent mechanism. NOD and B6.g7
BMDC were stimulated with 1 μg/mL LPS for 0, 30, 60, or 120 minutes. Cells were then
lysed and Western blot was performed on cell lysates with anti-phospho-GSK3β and total
GSK3 β antibodies (A). The fold changes for the ratios of phospho-GSK3β to total
GSK3β are shown (B). NOD and B6.g7 BMDC were stimulated with 1 μg/mL LPS for 0,
30, 60, or 120 minutes. Cells were then lysed and Western blot was performed on cell
lysates with anti-phospho-β-catenin-S675, anti--catenin, and anti-β-actin antibodies (C)
The ratios of phospho--catenin to total -catenin (D) and the ratios of phospho-catenin to -actin (E) are shown for each time point and for the average of three
independent experiments without LPS stimulation (F). NOD and B6.g7 BMDC were
lysed and Western blot was performed using anti-phospho-β-catenin-S552, anti-catenin, and anti-β-actin antibodies (G). The fold changes for the ratios of phospho-catenin to total -catenin (H) and the ratios of phospho--catenin to -actin (I) are shown.
The average fold change of phosphorylated -catenin on residue S552 from three
independent experiments from NOD and B6.g7 BMDC is shown (J). NOD and B6.g7
BMDC were treated with LY294002, H89, or a combination of both or DMSO vehicle
for 4 hours and then lysed. Western blot was performed using anti-phospho--catenin,
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anti-total--catenin, and anti--actin antibodies (K). The ratios of phospho--catenin to
-actin (L) and total -catenin to -actin (M) are shown. Data are representative of two or
more independent experiments.
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Figure 13. There is no difference in PKA or Akt expression in NOD and B6.g7
BMDC. BMDC were treated with or without LPS for 30 minutes. Western blot was
performed on these cell lysates using anti-PKA and anti--actin antibodies (A) or antiAkt and anti--actin antibodies (C). The fold change of PKA expression B) or Akt
expression D) is shown. Unstimulated (E) or LPS-stimulated (G) NOD and B6.g7
BMDC were lysed and Western blot was performed using anti-phospho-Akt at Thr308
and anti-pan-Akt antibodies. The fold changes of phospho-Akt to pan-Akt are shown (F)
and (H). LPS-stimulated and unstimulated NOD and B6.g7 BMDC were lysed and
Western blot was performed using anti-phospho-Akt at Ser473 and anti-pan-Akt
antibodies (I) or anti-phospho-PKA and total PKA antibodies (K). The fold changes of
phospho-Akt to pan-Akt (J) or phospho-PKA to total PKA (L) are shown. Data are
representative of two or more independent experiments.
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Figure 14: There are no differences in MAPK pathway activation in B6.g7 and NOD
BMDC. There are no differences in MAPK pathway activation in B6.g7 and NOD
BMDC. B6.g7 and NOD BMDC were stimulated with 1 μg/mL of LPS for 0, 5, or 15
minutes (A-B) or 0, 5, 15, 30, or 60 minutes (C-F) and whole cell lysates extracted.
Western blot was then performed using anti-phospho-p38 and anti-p38 antibodies (A-B)
or anti-phospho-ERK1/2 and anti-ERK1/2 antibodies (C-D). The fold changes for p38
(B) or p42 and p44 (D) activation is shown. Data are representative of two or more
independent experiments.
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DISCUSSION

The complex role of -catenin in inflammation
In this study, we have shown that -catenin is more highly expressed in NOD
BMDC than in BMDC from diabetes-resistant B6.g7 mice and in monocyte-derived DC
from diabetic patients as compared to mo-DC from healthy controls. In NOD mice, this
defective overexpression occurs in both the cytoplasm and nucleus at various stages of
disease including peri-insulitis, insulitis, and full-blown diabetes according to Western
blot, confocal microscopy, and FACS analysis, although FACS analysis shows a
progressively defective level of β-catenin expression as the disease progresses suggesting
that an increasing number of cells overexpress -catenin over the life span of the mice in
addition to higher levels of protein being expressed. Overall, these data indicate this
novel defect in -catenin expression may be a potential prognostic indicator for the
development of Type I diabetes.
Additionally, we have shown that inhibition of -catenin expression or activity in
NOD BMDC results in reduced IL-12 production, while forced expression of -catenin
or induction of activity in B6.g7 BMDC results in increased IL-12 production. Moreover,
in vivo experiments demonstrate that treatment with quercetin, a β-catenin inhibitor, can
reduce diabetes incidence and reduce the inflammatory environment that contributes to
disease development. These data demonstrate a potentially important role for -catenin
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in the production of a pathogenic cytokine that plays a key role in diabetes development.
Therapeutic reductions in the accumulation of -catenin or in its transcriptional activity
may therefore reduce the pathogenic inflammation important in Type I diabetes.
The role of -catenin in inflammation appears to be complex: several studies have
pointed to an anti-inflammatory role for -catenin [181, 186, 213] while others have
demonstrated a clear pro-inflammatory role for this protein [183-185, 187, 214]. On one
hand, -catenin has been found to play a role in the production of anti-inflammatory
molecules in lamina propria dendritic cells. [181]. Another group of studies have shown
that -catenin reduces Salmonella-induced inflammation in epithelial cells through an
NFB-dependent mechanism [178] or a mechanism involving inhibition of
GSK3mediated degradation [182]. On the other hand, -catenin is also associated
with increased inflammatory cytokine production in various cell types. In one study,
neutralizing antibody treatment against Wnt5a in mycobacterial products (PPD)-reactive
PBMC resulted in reduced IL-12 production by PBMC and reduced IFN production by
T cells [183], suggesting a role for β-catenin in Th1 cytokine regulation. Other
inflammatory cytokines appear to be regulated by -catenin signaling as well. -catenin
modulates IFN production in macrophages in response to VSV infection [184]. Yet
another study found that Wnt3A stimulation of microglia, which increases -catenin
expression, results in the expression of proinflammatory genes and the production of IL6, IL-12, and TNFα [185]. Interestingly, the activation of -catenin in APC-/- mice
resulted in the induction of a simultaneously pro- and anti-inflammatory environment in
the liver [187].
Finally, a group of studies coming from the Halleskog lab have shown that 86

catenin may be pro-inflammatory or anti-inflammatory even in the same cell type. In
these studies, Wnt3a signaling leading to -catenin stabilization in microglia was found
to be associated with Alzheimer’s-associated neuroinflammation [185]. However, in
another study, the same lab showed that pre-treating mouse microglia with LPS followed
by Wnt3a or Wnt5a treatment reduced the inflammatory cytokine response produced by
the LPS-treatment, even though Wnt3a or Wnt5a treatment alone induced a proinflammatory response [186]. Therefore, -catenin may act as an important master
regulator that modulates the pro- versus anti-inflammatory response depending on the
cell type, stimulus, and interactions between various stimuli.
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Figure 16. β-catenin as a master modulator of pro-inflammatory versus antiinflammatory responses.
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Interactions between -catenin and other signaling pathways in inflammation and
Type I diabetes
The interactions between -catenin and other signaling pathways, such as the
NFB pathway and the MAPK pathways are complex. It has been shown that Wnt3a
stimulation of microglia can induce inflammatory responses through the stimulation of
both -catenin signaling as well as ERK1/2 activation, but through distinct mechanisms
[214]. Wnt3a stimulates β-catenin stabilization through the canonical pathway through
the protein Disheveled while also stimulating the MAPK pathway through Phospholipase
C. Furthermore, Wnt5a can stimulate ERK activation and inflammation through catenin-independent mechanisms in microglia [215]. Additionally, phosphorylated p38
was observed in infiltrating CD4+ T cells in the pancreas of NOD mice. Treating NOD
mice with a p38 inhibitor reduced IFNγ production by spleen cells and reduced diabetes
incidence without affecting islet infiltration [216]. This study suggests that the p38
pathway may be involved in the pathogenic pro-inflammatory cytokine production that
leads to diabetes. However, we found no differences in either p38 or ERK1/2 activation
between NOD and B6.g7 BMDC, suggesting that the pro-inflammatory effect of catenin is not mediated through a MAPK-dependent mechanism.
While some studies have shown an inhibitory effect of -catenin on NFB
activation [212], others have shown a stimulatory effect [187]. Interestingly, several
studies have shown that NFB signaling is defective in NOD mice leading to increased
pro-inflammatory cytokine production [121, 217]. Our data suggests a new role for catenin in promoting NFB transcriptional activity in NOD mice. Additionally, our in
vivo experiments suggest that inhibiting the activity or expression of -catenin can
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downregulate pathogenic pro-inflammatory cytokine production and reduce disease
development.

Mechanisms of accumulation of -catenin in NOD BMDC
Determining the mechanisms that result in the accumulation of -catenin in NOD
BMDC may allow us to identify new targets for the development of therapies for Type I
diabetes. We have explored a variety of mechanisms that could lead to -catenin
overexpression in NOD BMDC. First, we found no differences in mRNA levels,
suggesting a lack of transcriptional defect. It has been previously shown that cells in the
submandibular glands of NOD mice overexpress E-cadherin, suggesting that defective
sequestration of -catenin at the cell membrane may be responsible for the accumulation
of -catenin in NOD BMDC [218]. However, we found no differences in the interaction
between these two proteins in NOD BMDC compared to control BMDC. Additionally,
when we examined GSK3 phosphorylation at Ser9, which inhibits the ability of the
kinase to phosphorylate -catenin at the degradation-targeting residues Ser33, Ser37, and
Thr41, we found no differences levels of inhibitory phosphorylation between NOD and
B6.g7 BMDC. Concordantly, we found no decrease in proteasomal degradation rates in
NOD BMDC. In fact it appears that -catenin degrades more quickly in NOD BMDC in
the presence of a proteasomal inhibitor, suggesting that other degradation pathways, such
as the lysosomal pathway, may be involved. Therefore it does not appear that -catenin
accumulation in NOD BMDC results from a defect in the GSK3-mediated degradation
mechanism that regulates -catenin expression in the cell.
β-catenin can be phosphorylated at other residues that lead to stabilization, as
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opposed to degradation. Akt phosphorylates β-catenin at Ser552 [150] and PKA
phosphorylates β-catenin at Ser552 and Ser675 [156]. Both of these phosphorylations
lead to accumulation of β-catenin and increased transcriptional activity [150, 156]. We
did find that a higher proportion of -catenin in NOD BMDC was phosphorylated at the
stabilizing residue Ser552 and Ser675 than in B6.g7 BMDC. Interestingly, inhibition of
PKA and/or Akt resulted in decreased abundance of phospho-β-catenin and -catenin,
indicating that the stabilizing activity of these two kinases are responsible for β-catenin
accumulation in NOD BMDC.
Very few studies on the role of the PI3K/Akt and PKA pathways in Type I
diabetes development have been performed. However, one study found that treatment of
NOD mice with a PI3K inhibitor, AS605240, led to prevention and reversal of diabetes.
Inflammatory cytokine production and IFN-production by splenic cells was decreased
while Tregs were expanded with this treatment. Additionally, high levels of
phosphorylated total Akt were observed in NOD splenocytes [219]. Interestingly, we
found that Akt was phosphorylated at residue Thr308 at higher levels in NOD as
compared to B6.g7 BMDC, while Ser473 was phosphorylated at higher levels in B6.g7
cells. The role of phosphorylation of Akt at Thr308 and Ser473 is controversial. It
appears that phosphorylation at both Thr308 and Ser473 is necessary for full activity
[147, 193]. Phosphorylation at Thr308 may be essential for Akt activity as demonstrated
by mutation of this residue leading to low Akt activity [220]. However, another study has
shown that phosphorylation at Ser473 may precede and prepare the kinase for
phosphorylation at Thr308 [221]. In this study, mutation of Ser473 led to reduced
phosphorylation at Thr308. Additionally, phosphorylation at Ser473 may negatively
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regulate phosphorylation at Thr308 as evidence by the fact that knocking out Rictor in the
beta cells of mice reduces the level of phosphorylation at Ser473 and greatly increases the
level of Thr308 phosphorylation [222]. This high level of phosphorylation at Thr308 and
low level at Ser473 correlated with reduced beta cell mass and insulin secretion. Our data
points to a negative regulatory role for Ser473 in which lower levels of phosphorylation
of Akt at Ser473 in NOD BMDC may allow for high levels of Thr308 phosphorylation
and increased Akt activity. The downstream effect of this increased activity is enhanced
stabilization and accumulation of -catenin through Ser552 phosphorylation.
Further studies need to be performed to determine the upstream mechanisms
leading to these high levels of phosphorylation at Thr308. Possible explanations include
defects in expression or activity of PDK1, which is responsible for phosphorylation at
Thr308 [147] and/or defects in expression or activity of mTOR, which is responsible for
phosphorylation at Ser473 [148]. Additional studies needed to elucidate the mechanisms
leading to increased phosphorylation by PKA include examining defects in the levels of
cyclic AMP, the molecule responsible for activation of PKA’s catalytic subunits. There
are also possibly defects in the expression and/or activity of adenylyl cyclase, the protein
which converts ATP to cAMP. Finally, in vivo studies using various PKA or Akt
inhibitors in NOD mice need to be performed. If Akt and/or PKA activation are
responsible for -catenin accumulation in NOD BMDC, inhibiting the activity of these
molecules in vivo should lead to decreased incidence, increased survival, and a decreased
inflammatory environment.
It remains unknown how Akt and/or PKA activity leads to increased
phosphorylation of β-catenin at Ser552 and Ser675 without leading to increased
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phosphorylation of GSK3β at the inhibitory phosphorylation Ser9 in NOD BMDC.
However, it has been proposed that there are two distinct pools of GSK3β in the cell: a
pool of free GSK3β that is susceptible to inhibitory phosphorylation by Akt and an axincomplexed pool that is protected from phosphorylation by Akt [223]. It is possible that
BMDC contain high levels of Axin-complexed GSK3β that is not available for
phosphorylation by Akt and/or PKA. This would allow for phosphorylation and
stabilization of β-catenin by highly active Akt and PKA without affecting the level of
phosphorylated GSK3β at Ser9.

Unexplored mechanisms of β-catenin accumulation in NOD BMDC
There are other mechanisms that we did not explore that may also contribute to catenin accumulation and enhanced transcriptional activity in NOD BMDC, including catenin acetylation, defective lysosomal degradation of -catenin, and defective
exosomal export of -catenin. Several studies have shown acetylation of -catenin at
various residues. Acetylation of Lys4 has been linked to negative regulation of
transcriptional activity of -catenin [224], while acetylation of Lys345 results in
increased affinity of -catenin for Tcf4, which could contribute to increased
transcriptional activity of -catenin [225]. A third study showed that high glucose
treatment of cells increased -catenin acetylation at Lys345 which resulted in increased
nuclear accumulation and transcriptional activity [226]. -catenin in NOD BMDC may
have defects in acetylation at either of these residues leading to increased nuclear
translocation and increased transcriptional activity resulting in increased proinflammatory cytokine production.
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Another possible mechanism by which -catenin may accumulate includes
defects in lysosomal degradation. Several studies have documented the ability of the
lysosome to degrade -catenin in a GSK-3/proteasome-independent mechanism. In one
study, a tea polyphenol induced lysosomal accumulation of excess -catenin in a colon
cancer model [227]. Another study demonstrated that Notch signaling in stem cells
resulted in negative regulation of active -catenin (non-phosphorylated at Ser33, 37 and
Thr41) through a lysosomal-dependent pathway [228]. Colocalization studies of catenin and the lysosome may reveal decreased lysosomal targeting of -catenin in NOD
BMDC or reduced ability of the lysosome to degrade excess -catenin.
Additionally, it has been shown that CD82 and CD9 induce -catenin export from
HEK239 cells and dendritic cells through exosomes [229]. Therefore, NOD BMDC may
have defects in exosomal export of excess -catenin as compared to B6.g7 cells.

β-catenin in human monocyte-derived DC and human Type I diabetes
-catenin is also overexpressed in human mo-DC from diabetic patients as
compared to healthy controls. Similar to the experiments in NOD mice, we found that
inhibiting the expression of -catenin with siRNA or the activity of -catenin with
quercetin resulted in decreased pro-inflammatory cytokine production. These data
indicate that -catenin may play an important role in human patients as well as in mice
and suggests that treatments targeting -catenin could be effective for human patients.
Because we could only delay diabetes in NOD mice treated with quercetin or -catenin
siRNA-transfected DC, simply reducing the inflammatory environment in Type I diabetes
individuals may not be sufficient. Therefore it may be necessary to reduce -catenin
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accumulation or activity in combination with other treatments, such as those aimed at
increasing tolerance. These possible treatments include administration of Lactobacilli
that induce the regulatory cytokine IL-10 [230] or transfer of Tregs [231], or anti-CD3
treatment [21]. However, inhibiting pathways upstream of-catenin may achieve both as
shown in the study inhibiting PI3K [219]. Inhibiting-catenin expression or activity as a
therapeutic strategy for preventing or treating Type I diabetes may provide several
advantages, including the specific reduction of IL-12, the hallmark pathogenic cytokine
involved in Type I diabetes.

Conclusion
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Figure 17. A scenario leading to β-catenin accumulation and pro-inflammatory
cytokine production in NOD BMDC but not B6.g7 BMDC.
Overall, we have found that overexpression of -catenin in NOD BMDC leads to
increased pathogenic pro-inflammatory cytokine production and inhibiting -catenin
activity in vivo leads to a decrease in the pro-inflammatory environment. -catenin
accumulates as a result of increased phosphorylation of Akt at Thr308, which leads to
increased phosphorylation of -catenin at the stabilizing residue Ser552 and Ser675.
Additionally, -catenin accumulation leads to increased pro-inflammatory cytokine
production through an NFκB-dependent mechanism.
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